Elucidating Cause-Effect Relationships between Extracellular Matrix Signaling and Mesenchymal Stem Cell Differentiation by Becerra-Bayona, Silvia M.
  
ELUCIDATING CAUSE-EFFECT RELATIONSHIPS BETWEEN 
EXTRACELLULAR MATRIX SIGNALING AND MESENCHYMAL STEM CELL 
DIFFERENTIATION 
 
A Dissertation 
by 
SILVIA MILENA BECERRA-BAYONA  
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
  
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,   Mariah Hahn 
Committee Members,  Zhilei Chen 
  Arul Jayaraman 
  Mike McShane 
Intercollegiate Faculty Chair, Ibrahim Karaman 
 
August 2013 
 
Major Subject: Materials Science and Engineering 
 
Copyright 2013 Silvia Milena Becerra-Bayona 
 ii 
 
ABSTRACT 
 
Mesenchymal stem cell (MSC) differentiation is known to be influenced by a 
range of environmental stimuli. MSC-based bone regeneration strategies would benefit 
from the identification of scaffold material properties which intrinsically promote 
osteoblast lineage progression. The aim of this work was to contribute to the 
understanding of elucidating cause-effect relationships between extracellular matrix 
(ECM) signaling and osteogenic MSC differentiation using poly(ethylene glycol) 
diacrylate (PEGDA) hydrogels as a material platform. First, the effect of several ECM 
proteins associated with bone morphogenesis or bone fracture healing on MSC 
osteogenesis was investigated. Second, collagen-mimetic proteins (Scl2) were modified 
in order to incorporate them in a 3D network, and cell adhesion and activation of cell 
signaling were evaluated, as well. Finally, the influence of integrin α1 and α2 binding on 
human MSC (hMSC) osteogenesis was investigated toward the goal of deconvoluting 
the impact of integrin-based interactions on associated cell behavior. 
In terms of the osteoinductivity of select ECM components, the results showed 
that both FG and LN enhanced the osteogenic response of encapsulated MSC cells. In 
addition, the integrin-based interactions supported by these ECM components indicated 
that integrin α2 and α6 appeared to play an important role in MSC osteogenesis. 
Regarding Scl2 protein studies, Scl2-1, Scl2-2, and Scl2-3 were functionalized 
with photocrosslinking sites to enable incorporation into a 3D hydrogel matrix. 
characterization studies confirmed that the functionalization of the Scl2 proteins did not 
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disrupt triple helix conformation, integrin binding, or cell adhesion. Also, initial cell 
studies confirmed specific hMSC adhesion to Scl2 proteins and appropriate activation of 
different MAP kinase pathways. 
Finally, Scl2 proteins were conjugated into PEGDA hydrogels and their effect on 
hMSC osteogenesis was evaluated. The results indicated that both PEG-Scl2-2 and PEG-
Scl2-3 were osteoinductive, but in different ways. Therefore, to gain insight into the 
origins of the observed osteogenic responses, the influence of p38 pathway in 
osteogenesis of hMSC was investigated in order to establish its potential causative 
relationship with Scl2 proteins. The results of the p38 inhibition studies suggested p38 
pathway may regulate osteogenesis in hMSCs. Further research is needed for 
investigation of detailed mechanism of osteogenesis regulation.  
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CHAPTER I  
INTRODUCTION 
 
1.1. PROBLEM STATEMENT 
 
Tissue engineering combines cells, soluble stimuli and/or a matrix (biomaterial 
scaffold) to guide regeneration. This paradigm has proven to be powerful and has 
transformed our understanding of the cell and its interactions with its environment. The 
extracellular matrix (ECM), long considered a passive structural component of tissues, is 
now understood to be a rich source of biochemical and biophysical cues which direct 
cell behavior. Indeed, a seemingly bewildering array of matrix-mediated stimuli are now 
recognized to impact cell responses, including matrix-induced organization and rigidity 
of the actin cytoskeleton, the identity and concentration of extracellular biochemical 
cues, and the nanoscale clustering of bioactive ligands. In face of this array of complex 
and often interdependent signals, it is difficult to rationally design biomaterials to elicit 
desired cell behavior. 
The proposed research activities focused on developing a platform to enable the 
exploration of the impact of various matrix-mediated stimuli on mesenchymal stem cell 
(MSC) signaling and osteogenic lineage progression. A unique biosynthetic hydrogel, 
based on the crosslink of diacrylate-derivatized poly(ethylene glycol) (PEGDA) with 
collagen-mimetic proteins (Scl2s) was employed. Collagen-mimetic protein (Scl2.28) is 
a recently discovered protein which contains the GXY repeats and triple helical structure 
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characteristic of native collagen, but lacks collagen’s array of cell adhesion, cytokine 
binding, and enzyme cleavage sites. Thus, Scl2 provided a “blank-slate” into which 
desired collagen-based, cell adhesion sequences can be programmed by site-directed 
mutagenesis while maintaining the triple helical context natively associated with these 
motifs. In evaluating cell signaling, the focal adhesion kinase (FAK) and mitogen 
activated protein kinase (MAPK) pathways were explored due to their known roles in 
regulating cell responses to integrin-mediated stimuli. The research objectives of this 
work were to: 
 
- Investigate the effects of several ECM proteins associated with bone 
morphogenesis or bone fracture healing on MSC osteogenic differentiation. 
- Functionalize collagen-mimetic proteins and validate a 3D hydrogel system 
incorporating these proteins. 
- Confirm integrin-adhesion specificity of Scl2 proteins as well as appropriate 
activation of cell signaling. 
- Investigate the effect of collagen-mimetic proteins in human mesenchymal 
stem cell osteogenesis. 
- Conduct preliminary studies in order to elucidate the causative mechanisms 
underlying MSC osteogenic response to integrin-mediated bioactivity by 
inhibiting the p38 MAP kinase signaling pathway.  
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1.2. BACKGROUND 
 
Tissue engineering holds great promise for the treatment of millions of people 
worldwide suffering from organ damage or failure [1-3]. However, several obstacles 
currently hinder the rapid progress of this field. Two of the major limitations involve: (1) 
the issue of cell source [2] and (2) the difficulties associated with biomaterial design due 
in part to the complexity of cell-matrix interactions. Until recently, most tissue 
engineering research focused on building new tissues using adult somatic cells. 
However, adult cells tend to display low rates of matrix production and many 
differentiated adult cells have limited proliferative and functional regenerative capacities 
[2]. In addition, most organs contain a range of cell types organized into complex 
interconnecting structures. Thus, organ repair generally requires that multiple different 
adult cell types be isolated and recombined into organized, functional units, further 
complicating regeneration. 
Recent advances in adult MSC research have shown these cells to be a promising 
patient-derived cell source that may address many of the limitations of differentiated 
adult cells [3, 4]. Not only are they capable of extensive proliferation, but they have the 
capacity to differentiate into a range of cell types [3, 5]. There are currently two general 
approaches to harnessing the multipotent character of MSCs for tissue regeneration. In 
one approach, MSCs are first separately differentiated into each of the desired cell types, 
after which the differentiated cells are organized and combined into a functional 
structure [3]. The second major approach generally involves placing MSCs within a 3D 
 4 
 
biomaterial context and then providing specific spatial and temporal cues to drive the 
MSCs to differentiate, interconnect, and organize into a functional organ [3, 6]. In the 
former approach, the tissue engineer has greater control over the differentiated cell 
populations but generally must fabricate their structural organization, which constitutes a 
major challenge due to the complex arrangement of elements underlying cell 
extracellular matrix functionality. 
However, a major limitation to the use of MSCs in tissue regeneration is the 
conflicting literature base regarding matrix-mediated stimuli that drive specific lineage 
progression. Despite a number of advances, understanding of MSC behavior is not yet 
sufficient to enable the rational selection of stimuli to elicit desired cell responses [7, 8]. 
Indeed, the literature contains a number of examples of the same apparent stimuli being 
applied to MSCs with markedly different outcomes [9-12]. For instance, a recent study 
found that MSCs cultured in alginate gels in the presence of TGF-β and dexamethasone 
displayed decreased chondrogenic potential with increasing levels of integrin-adhesion 
peptide RGD [12]. In contrast, a separate study reported that MSCs cultured in PEG-
based hydrogels, also in the presence of TGF-β and dexamethasone, showed increased 
chondrogenic potential with increasing RGD concentration [11]. Since neither PEG [13] 
nor alginate[14] interact significantly with cells and since neither study characterized gel 
modulus, the source of the discrepancy between the two studies is, as is often the case, 
unclear. Such inconsistencies limit our ability to rationally guide MSC lineage 
progression. 
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A potential source of the inconsistency in literature may arise from the 
complexity of the native biopolymers often used in the studies [15-18]. Aside from 
issues associated with variations in biopolymer purity, biopolymers, such as collagen, 
are complex molecules containing an array of signals which guide cell behavior [19-21]. 
These signals include cell adhesion sites, enzyme cleavage sequences, as well as growth 
factor and cytokine binding regions [20, 21]. These intricate biological interactions make 
it difficult to deconvolute the impact of individual biopolymer motifs on associated 
cellular signaling.  
To address this challenge, many researchers have employed integrin-blocking 
peptides or antibodies to reduce the ability of cell to interact with specific biopolymer 
sequences [11, 12]. These studies have yielded significant insight into the influence of 
various integrins and specific ECM sequence motifs on cell behavior. However, they are 
limited in that they do not account for the fact that the cells continue to receive 
remaining ECM signals; in other words, they do not account for the context in which the 
loss of signaling is occurring. This observation is significant because cells do not 
generally respond additively to signals they receive from the surroundings. Thus, 
recognition and, if possible, control over the contextual presentation of a given stimulus 
is critical to the development of cause-effect relationships.  
To overcome the obstacles associated with biopolymer signaling context, many 
researchers have explored the use of bioactive peptides, such as RGD, in place of full 
biopolymers [22-24]. This approach has greatly advanced our understanding of cell 
responses to matrix-mediated biochemical cues. Unfortunately, this approach removes a 
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critical aspect of the 3D context provided by the parent biomolecule, namely the regional 
protein folding. It also has limited capacity for the re-introduction of additional 
biopolymer signals for studies of synergistic interactions among biopolymer signaling 
motifs.  
An underlying premise of this research proposal is that providing MSCs with the 
spatial and temporal signals needed to direct functional organ regeneration requires a 
deeper understanding of MSC responses to external stimuli than currently exists. 
Therefore, we propose to investigate the effects of native ECM constituents as well as 
ECM mimics on MSC osteogenic differentiation in 3D contexts. In order to achieve this, 
poly(ethylene glycol) diacrylate (PEGDA) hydrogel networks will be used as the 
material platform due to the broad tunability of their mechanical properties, their 
previous use in bone regeneration applications as well as their biological “blank slate” 
nature. The latter feature of PEGDA hydrogels allows initial cell interactions with the 
matrix to be isolated to the proteins specifically tethered to the scaffold. To investigate 
potential causative signaling mechanisms regulating MSC differentiation in response to 
specific matrix-mediated stimuli, we conducted preliminary studies in which we 
inhibited p38 in the FAK/MAP kinase signaling cascade and characterized associated 
changes in cell response. Understanding the dominant signaling underlying particular 
cell behavior will allow biomaterials to be specifically designed to modulate these 
signaling cascades. We hypothesize that there is a subset of external stimuli which 
dominate cell responses and that the discovery of these stimuli, and the key signaling 
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mechanisms through which they actuate cell behavior, will allow us to predict, and 
therefore dictate, cell behavior.  
The understanding gained from this research will contribute to the rational 
development of biomaterial matrices designed to “program” or evoke desired MSC 
lineage commitment via modulation of specific input stimuli and/or signaling elements. 
This would represent a significant advance in biomaterials design for complex organ 
regeneration. 
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CHAPTER II 
INFLUENCE OF SELECT EXTRACELLULAR MATRIX PROTEINS ON 
MESENCHYMAL STEM CELL OSTEOGENIC COMMITMENT IN THREE-
DIMENSIONAL CONTEXTS
*
  
 
2.1. OVERVIEW 
 
Mesenchymal stem cells are being increasingly recognized as a viable cell source 
for bone regeneration applications due to their ability to be expanded in vitro and to 
differentiate into a number of cell lineages. Thus, the ability to promote MSC osteogenic 
differentiation via the manipulation of scaffold material properties would be beneficial. 
The current work examines the influence of select extracellular matrix (ECM) proteins 
on MSC osteogenesis toward the goal of developing scaffolds with osteoinductive 
properties. Fibrinogen (FG), fibronectin (FN) and laminin-1 (LN) were chosen for 
evaluation due to their known roles in bone morphogenesis or bone fracture healing.  
 
 
 
 
                                                 
*Reprinted with permission from “Influence of select extracellular matrix proteins on mesenchymal stem 
cell osteogenic commitment in three-dimensional contexts” by Silvia Becerra-Bayona, Viviana Guiza- 
Arguello, Xin Qu, Dany J. Munoz-Pinto, Mariah S. Hahn, 2012. Acta Biomaterialia, 8, 4397-4404, 
Copyright [2012] by Acta Materialia Inc. Published by Elsevier Ltd. 
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These proteins were conjugated into poly(ethylene glycol) diacrylate (PEGDA) 
hydrogels and their effects on encapsulated 10T½ MSCs were evaluated. Specifically, 
following 1 week of culture, mid-term markers of various MSC lineages were examined 
in order to assess the strength and specificity of the observed osteogenic responses. 
PEG–LN gels demonstrated increased levels of the osteogenic transcription factor 
osterix relative to day 0 levels. In addition, PEG–FG and PEG–LN gels were associated 
with increased deposition of bone ECM protein osteocalcin relative to PEG–FN gels and 
day 0. Importantly, the osteogenic response associated with FG and LN appeared to be 
specific in that markers for chondrocytic, smooth muscle cell and adipocytic lineages 
were not similarly elevated relative to day 0 in these gels. To gain insight into the 
integrin dynamics underlying the observed differentiation results, initial integrin 
adhesion and temporal alterations in cell integrin profiles were evaluated. The associated 
results suggest that α2 and α6 integrin subunits may play key roles in integrin-mediated 
osteogenesis. 
 
2.2. INTRODUCTION 
 
Mesenchymal stem cells are being increasingly recognized as a viable cell source 
for bone regeneration applications due to their ability to be expanded in vitro and to 
differentiate into a number of cell lineages. However, MSC differentiation is known to 
be influenced by a range of environmental stimuli. Thus, MSC-based bone regeneration 
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strategies would benefit from the identification of scaffold material properties which 
promote osteoblast lineage progression. 
A number of two-dimensional (2-D) studies have demonstrated MSC osteogenic 
differentiation to be tightly regulated by cellular interactions with the surrounding 
extracellular matrix (ECM) [16, 18, 24-34]. However, comparatively little is known 
regarding the effects of various ECM components in regulating MSC osteogenesis in 
three-dimensional (3-D) scaffold environments [17, 35, 36]. This is significant since 
recent studies suggest that effects observed in two dimensions may not be indicative of 
the effects of the same scaffold variables in more biomimetic 3-D culture systems [37-
39]. Therefore, the current work focuses on elucidating the influence of select ECM 
constituents on MSC osteogenic differentiation in 3-D contexts.  
Towards this goal, we incorporated specific ECM molecules into hydrogel 
scaffolds designed to have moduli within the ‘‘osteogenic’’ range identified in the 3-D 
human and mouse MSC studies of Huebsch et al. [40]. In selecting molecules for 
examination, we chose to focus on several ECM proteins associated with bone 
morphogenesis (fibronectin [41] and laminin-1 [42, 43]) and/or bone fracture healing 
(fibrinogen [44]). These proteins were then conjugated into poly(ethylene glycol) 
diacrylate (PEGDA) hydrogel networks. PEGDA hydrogels were selected as the base 
scaffold due to the broad tunability of their mechanical properties and their previous use 
in bone regeneration applications [45-48]. In addition, pure PEGDA hydrogels function 
as biological ‘‘blank slates’’ in that they do not significantly adsorb cell adhesive serum 
proteins and therefore do not intrinsically promote cell adhesion [13]. Thus, cell 
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interactions with PEGDA gels are initially isolated to the proteins specifically tethered to 
the scaffold as well as the interactions supported by these proteins (e.g. growth factor 
binding). 
In the present study, 10T½ MSCs were encapsulated within PEGDA hydrogels 
containing defined amounts of fibronectin (FN), fibrinogen (FG) or laminin-1 (LN). The 
levels of various markers of osteoblast, chondrocytic, smooth muscle cell and adipocytic 
fates were then monitored with time in culture toward assessing the strength and 
specificity of observed osteogenic responses. Due to the critical role of integrins in 
transducing the signals provided by glycoproteins such as FN, FG and LN [49], initial 
integrin adhesion profiles as well as temporal alterations in cell integrin profiles were 
also characterized. 
 
2.3. MATERIAL AND METHODS 
 
2.3.1. Polymer synthesis and characterization 
 
2.3.1.1. PEG-diacrylate synthesis 
PEGDA was prepared as previously described [50] by combining 0.1 mmol ml
-1
 
dry PEG (10 kDa, Fluka), 0.4 mmol ml
-1
 acryloyl chloride and 0.2 mmol ml
-1
 
triethylamine in anhydrous dichloromethane and stirring under argon overnight. The 
resulting solution was washed with 2 M K2CO3 and separated into aqueous and 
dichloromethane phases to remove HCl. The organic phase was subsequently dried with 
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anhydrous MgSO4, and PEGDA was precipitated in diethyl ether, filtered and dried 
under vacuum. Acrylation of the PEG end hydroxyl groups was characterized by proton 
nuclear magnetic resonance (
1
H-NMR) to be ~95%. 
 
2.3.1.2. Synthesis of acrylate-derivatized proteins 
Proteins FN (human plasma, BD Biosciences), FG (human plasma, Sigma 
Aldrich) and LN (mouse, BD Biosciences) were lightly functionalized in their folded 
state by reaction with acryloyl-PEG-N-hydroxysuccinimide (ACRL-PEG-NHS, 3.4 kDa, 
Nektar) at a 1:2 M ratio at pH 8.5 [50]. The resulting acrylate-derivatized products were 
purified by dialysis against a 100 kDa membrane, lyophilized and stored at -20 °C until 
use. ACRL–PEG conjugation to the target proteins was confirmed using 1H-NMR. A 
representative 
1
HNMR spectrum for acrylate-derivatized FG is shown in Figure 1.  
To confirm the ability of the modified proteins to be incorporated within PEGDA 
hydrogel networks, hydrogel precursor solutions were prepared with 0.5 mg ml
-1
 protein 
and 100 mg ml
-1
 PEGDA (10kDa). Following the addition of 10 µl ml
-1
 of a 300 mg ml
-1
 
solution of UV photoinitiator 2,2-dimethoxy-2-phenyl-acetophenone (DMAP) in N-
vinylpyrrolidone (NVP), gels were polymerized by 4 min exposure to long-wave UV 
light (Spectroline, ~6 mWcm
-2
, 365 nm). The gels were then immersed in PBS 
overnight, after which they were transferred to a 0.12 M NaOH solution to hydrolyze the 
PEGDA crosslinks and release encapsulated protein. The levels of protein released were 
compared to the levels in the precursor solution using the CBQCA assay (Invitrogen), 
and the average level of protein incorporation was found to be consistent across protein 
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types at 86.7 ± 7.2%. In addition, to assess the ability of cells to interact with proteins 
incorporated into the hydrogel network, 10T½ cells were seeded onto the surface of each 
gel formulation. Cell adhesion and spreading were confirmed for each PEG–ECM gel 
type (Figure 2). 
 
 
Figure 1. 1H-NMR spectrum of functionalized FG confirming conjugation of FG with ACRL-PEG-NHS. 
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Figure 2. PEG-functionalized protein hydrogels were fabricated by combining 100 mg ml-1 PEGDA 
(10kDa) with photoinitiator (DMAP in NVP) and 0.5 mg ml
-1
 functionalized protein of FG, FN and LN. 
PEGDA hydrogel served as a negative control. 10T½ cells were stained with 5µM CellTracker Orange 
CMTMR (5-(and-6)-(((4-chloromethyl)benzoyl)amino)Tetramethylrhodamine) and seeded at a density of 
6,000 cells cm
-2
 on the surface of the hydrogels. Attached cells were allowed to spread for 3 hours and 
imaged by fluorescence microscopy. The scale bar applies to all images and equals 100 µm.  
 
 
2.3.2. Cell culture, initial characterization and encapsulation  
 
Cryopreserved 10T½ mouse MSCs (American Type Culture Collection; ATCC) 
at passage 2 were thawed and expanded in monolayer culture per ATCC protocols. Prior 
to encapsulation, cells were maintained at 37 °C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM, Hyclone) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS, Hyclone). Cells at passage 4–6 were termed ‘‘day 0’’ and were 
harvested and allocated for either protein extraction, integrin blocking studies or 
hydrogel encapsulation. 
 
2.3.2.1. Protein extraction 
Proteins were extracted from day 0 10T½ cells by the addition of Trizol 
(Invitrogen) per manufacture’s protocols. The resulting solutions were centrifuged, and 
each supernatant was mixed with chloroform (Sigma), vigorously shaken for 15 s and 
centrifuged. The lower protein-rich phenol–chloroform phase of each sample (n = 4) was 
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mixed with ethanol to precipitate residual DNA. The resulting phenol–ethanol phase was 
transferred to a 3.4 kDa SnakeSkin dialysis membrane (Pierce). The solution was 
dialyzed for ~60 h at 4 °C against an aqueous solution of 0.1% sodium dodecyl sulfate 
(SDS), with buffer exchange every 18 h. By the end of the third 18 h dialysis period, the 
samples had partitioned into three phases: (1) a supernatant, (2) a globular mass and (3) 
a colorless, viscous liquid. The globular mass, containing the bulk of sample proteins 
[51], was resuspended in PBS containing 0.5% SDS and 1% Triton X-100. The isolated 
sample proteins were subsequently used in quantitative ELISA assays. 
 
2.3.2.2. Integrin blocking studies 
Standard adhesion blocking studies were performed to determine the integrin 
alpha subunits through which the 10T½ cells initially interacted with the PEG–ECM 
gels. In brief, functionalized FG, FN and LN were resuspended in PBS at 100 µg ml
-1
, 
after which they were applied to a 96-well, high protein binding plate at 100 µl per well 
for 12 h at 4 °C. The wells were then blocked with 3% bovine serum albumin (BSA). 
Harvested 10T½ cells were washed with PBS and resuspended in serum-free DMEM 
supplemented with 1 mM Ca
2+
 and 1 mM Mg
2+
. Cells were then exposed to 50 µg ml
-1
 
of α1, α2, α5, αv or α6 integrin antibodies or to 50 µg ml
-1
 of appropriate negative control 
antibodies for 30 min at room temperature. Further details regarding antibodies are given 
in Table 1. The cell suspensions were subsequently applied to the coated wells at 10,000 
cells cm
-2
. Following 30 min incubation at 37 °C and 5% CO2, wells were rinsed three 
times with PBS. Adherent cells were then lysed, and the number of adherent cells in 
 16 
 
each well was measured using a lactate dehydrogenase assay kit (Roche). Percentage 
inhibition was evaluated relative to the corresponding negative control. At least five 
sample wells per antibody were analyzed for each protein type. 
 
Table 1. Antibodies employed in adhesion blocking, immunostaining, and ELISA assays. 
Antibody Clone Supplier 
Adhesion 
Blocking 
Immunostaining ELISA 
Integrin α1 Ha31/8 BD    
Integrin α2 HMα2 BD    
Integrin α5 HMα5-1 BD    
Integrin αv RMV-7 BD    
Integrin α6 NKI-GoH3 Chemicon    
Osterix M-15 SCBT    
Osteocalcin M-15 SCBT    
Osteopontin AKm2A1 SCBT    
PPARγ H-100 SCBT    
A-FABP C-15 SCBT    
Sox 9 C-20 SCBT    
Collagen II N-19 SCBT    
Myocardin H-300 SCBT    
SM22α P-15 SCBT    
Integrin α1 F-19 SCBT    
Integrin α2 N-19 SCBT    
Integrin α5 P-19 S CBT    
Integrin αv N-19 SCBT    
Integrin α6 N-19 SCBT    
Β-actin 13E5 CS    
 
†
Abbreviations: BD – BD Pharminogen; SCBT – Santa Cruz Biotechnology; CS: Cell Signaling 
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2.3.2.3. Cell encapsulation and culture 
Hydrogels were fabricated by preparing: (1) a 20 wt.% PEGDA solution in 
HEPES-buffered saline (HBS) and (2) separate solutions of 1 mg ml
-1
 acrylate-
derivatized FN, FG or LN in HBS. A 300 mg ml
-1
 solution of DMAP in NVP was added 
at 2% (v/v) to the PEGDA mixture. The PEGDA and protein solutions were then 
separately sterilized by filtration, after which each protein solution was mixed with an 
equal volume of the 20 wt.% PEGDA solution. Harvested 10T½ cells were resuspended 
in the resulting precursor solutions at 1 x 10
6
 cells ml
-1
. The cell suspensions were then 
pipetted into molds composed of two glass plates separated by 0.5 mm polycarbonate 
spacers and polymerized by 4 min exposure to long-wave UV light (Spectroline, 
~6mWcm
-2
, 365 nm). A set of the resulting hydrogels were harvested for ‘‘day 0’’ 
analyses as described in the following section. The remaining hydrogel slabs were 
transferred to Omnitrays (Nunc) fitted with four sterile polycarbonate bars to 
simultaneously prevent gel flotation and prevent gel contact with the tray bottom. 
Hydrogels were immersed in DMEM supplemented with 10% FBS, 100 U ml
-1
 
penicillin and 100 mg l
-1
 streptomycin. Gels were maintained at 37 °C and 5% CO2, with 
media changes every 2 days. 
 
2.3.3. Day 0 hydrogel characterization 
 
2.3.3.1. Average mesh size 
PEGDA hydrogel mesh structure cannot be visualized using standard techniques  
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such as scanning electron microscopy. In the present study, average hydrogel mesh size 
was therefore characterized via a series of dextran diffusion experiments based on an 
adaptation of the methodology of Watkins and Anseth [52]. In brief, samples were 
collected from the freshly prepared PEG– ECM hydrogels and allowed to swell 
overnight at 37 °C in PBS containing 0.05% azide (PBS-azide). Eight-millimeter-
diameter discs were then harvested from each gel formulation, and solutions containing 
0.05 mg ml
-1
 fluorescently labeled dextran (10 kDa, Invitrogen) in PBS-azide were 
added at 1 ml per hydrogel disc. Dextran solutions were allowed to diffuse into the 
hydrogels for 24 h at 37 °C. Each gel disc was then gently blotted and transferred to 1 ml 
fresh PBS-azide. Dextran that had penetrated into the hydrogels was then permitted to 
diffuse out into the surrounding solution at 37 °C. After 24 h, the fluorescence of the 
PBS-azide solution surrounding each disc was measured at ex/em 488/532. Dextran 
standard curves were used to convert each fluorescence signal to a concentration. For 
each hydrogel, the measured dextran concentration was divided by gel weight [53]. The 
resulting value served as a quantitative indicator of hydrogel permissivity. 
 
2.3.3.2. Hydrogel mechanical properties 
Samples were collected from each freshly prepared hydrogel formulation and 
allowed to swell overnight in PBS-azide. Eight mm discs (n = 4 per formulation) were 
then cored from each gel sample and mechanically tested under unconfined compression 
using a DMA 800 (TA Instruments). Following application of a 0.01 N preload, each 
disc was subjected to compression at a rate of 0.1 mm min
-1
. The compressive modulus 
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of each hydrogel was extracted from the resulting stress–strain data over a 10–25% 
strain range. 
 
2.3.3.3. Cell density 
Samples (n = 4) were collected from each freshly prepared hydrogel formulation 
following 24 h immersion in culture media. Hydrogel samples were digested for 72 h at 
37 °C in 1 ml of 0.12 M NaOH per 0.2 g hydrogel wet weight [54, 55]. Aliquots of the 
hydrolyzed samples were neutralized, and their DNA content determined using the 
Invitrogen PicoGreen assay [56]. DNA measures were translated to cell number using a 
conversion factor of 6.6 pg DNA per cell [57]. Calf thymus DNA (Sigma) subjected to 
the same association with PEGDA and to the same digestion conditions as the samples 
served as a standard. 
 
2.3.4. Endpoint analyses 
 
At day 7 of culture, samples were harvested from each hydrogel formulation for 
mechanical, mesh size, DNA, ELISA and histological analyses. Samples collected for 
histological analyses (n = 4–8 per formulation) were fixed in 10% formalin for 30 min 
and embedded in Tissue-Tek freezing medium. Samples harvested for mechanical (n = 4 
per formulation), mesh size (n = 4 per formulation) and DNA (n = 4 per formulation) 
assessments were evaluated according to the same protocols as the day 0 specimens. 
Similarly, samples harvested for ELISA analyses (n = 6–9 per formulation) were 
 20 
 
homogenized in Trizol using a Bead-Beater homogenizer (Biospec), after which sample 
proteins were isolated as described for day 0 specimens. 
 
2.3.4.1. ELISA analyses 
Proteins extracted from the day 0 cells and the day 7 constructs were evaluated 
for various lineage markers and integrin alpha subunits via competitive ELISAs. Further 
details regarding the antibodies employed are given in Table 1. For each antibody 
examined, high binding EIA 96-well plates (Costar) were coated overnight at 4 °C with 
appropriate competitive peptide. The concentration of applied competitive peptide was 
200 ng per well, except for b-actin (50 ng per well). The coated wells were then blocked 
with BSA and rinsed with PBS. Aliquots of each sample were incubated with primary 
antibody for 1 h, after which the sample–antibody mixtures were applied to coated wells 
for 1 h. Standard curves were similarly prepared by incubating primary antibody with 
varying levels of competitive peptide for 1 h, followed by solution application to coated 
wells. For both samples and standards, primary antibody which had bound to the coated 
wells was detected using an appropriate HRP-conjugated secondary antibody (Jackson 
Immunoresearch), followed by the application of 2,20-azino-bis(3-ethylbenzthiazoline-
6-sulphonic acid) (Sigma) and monitoring of absorbance at 410 nm. Each target protein 
was analyzed in duplicate for each sample (n = 6–9 per day 7 gel type; n = 4 for day 0) 
and normalized to the housekeeping protein b-actin. 
 
 
 21 
 
2.3.4.2. Histological analyses 
Bone ECM deposition (osteopontin and osteocalcin) was further analyzed using 
standard immunohistochemical techniques. In brief, 35 µm sections were cut from each 
embedded histological sample (n = 4–8 per formulation) using a cryomicrotome. 
Rehydrated sections were blocked for peroxidase for 30 min followed by 30 min 
exposure to Terminator (Biocare Medical). Primary antibodies for osteopontin and 
osteocalcin were diluted in PBS containing 3% BSA and then applied to the sections for 
1 h. Bound primary antibody was detected using HRP-conjugated secondary antibody 
(Jackson Immunoresearch) followed by the application of chromogens AEC (LabVision) 
or DAB (Biocare Medical). For the detection of intracellular differentiation markers 
(myocardin and PPARγ), rehydrated sections were permeabilized (10 mM HEPES, pH 
6.8, 100 mM NaCl, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton X-100) for 30 min prior 
to Terminator application. Further details regarding the antibodies employed are given in 
Table 1. 
Stained sections were imaged using a Zeiss Axiovert microscope, and cell counts 
were carried out to semi-quantitatively evaluate immunostaining results for intracellular 
markers myocardin and PPARγ. These counting assessments were conducted according 
to established methods [45, 58, 59] on sections from each sample (n = 4–8 per gel 
formulation). For each cell, i, in a given section, a single observer blinded to outcome 
assigned a staining intensity, di, on a scale of 0–3 (0 = ‘‘no staining’’ and 3 = ‘‘highest 
intensity among all formulations for that antibody’’). The cumulative staining intensity, 
d, for a given antibody in a particular section was calculated using the following 
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equation: d=(∑ di) (total cell number). In addition, since deposited ECM remained 
localized around the parent cells in each hydrogel formulation, as is characteristic for 
PEGDA gels [60], the relative levels of osteocalcin and osteopontin among hydrogel 
formulations were also evaluated by cell counts per the above procedure. Osteocalcin 
counts were used to internally validate the counting approach by direct comparison with 
corresponding quantitative ELISA data (Figure 3). The degree of correlation between the 
two assessment techniques was 98.9% by Pearson’s correlation coefficient method. 
 
 
Figure 3. Comparison of osteocalcin measures by ELISA and cell counting assessments. For ELISA 
assays, 6-9 samples per formulation were analyzed. For cell counts, sections from 4 separate discs of each 
formulation were evaluated.  The degree of correlation between the two assessment techniques was 98.5% 
by Pearson’s correlation coefficient method. 
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2.3.5. Statistical analyses 
 
Data are reported as mean ± standard deviation. Comparison of sample means 
was performed by ANOVA followed by Tukey’s post hoc test (SPSS software), p < 
0.05. 
 
2.4. RESULTS 
 
2.4.1. Hydrogel material properties and cell density 
 
A range of scaffold properties, including modulus, permeability and degradation 
rate, have been found to impact MSC lineage progression. Therefore, in order to 
attribute differences in 10T½ cell behavior across hydrogel formulations specifically to 
initial differences in gel protein composition, it was important that the remaining 
hydrogel material properties could be considered consistent across gels. Hydrogels 
formed from pure PEGDA degrade slowly (over a period of 1–2 years) and resist cell-
mediated gel contraction, ensuring consistent bulk gel properties over a broad time range 
[55, 56, 61-63]. In the present study, a 200:1 weight ratio of PEGDA to protein was 
therefore selected to ensure that the network properties of the resulting gels would be 
dominated by PEGDA. To confirm this, the modulus, mesh size, thickness and mass of 
the PEG–ECM hydrogels were characterized both at day 0 and at day 7. 
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As shown in Table 2, the initial elastic moduli of the PEG–FG, PEG–FN and 
PEG–LN gels were similar at ~33 kPa. Importantly, each of these initial moduli were 
within the osteogenic range identified by the 3-D studies of Huebsch et al. [40]. To 
assess degradation and cell-mediated contraction, hydrogel modulus and thickness were 
evaluated across time in culture.  
Comparison of initial and endpoint mechanical data indicated that, although the 
modulus decreased by ~15% over the 7 day culture time for each gel formulation, 
hydrogel modulus remained consistent across formulations (Table 2). Similarly, average 
mesh size was consistent across hydrogels at both day 0 and day 7 (Table 2). The initial 
and endpoint thickness data for 8 mm gel discs indicated a negligible alteration in gel 
volume with time. In addition, net cell proliferation and loss were examined for each 
PEG–ECM hydrogel over the 7 day culture period. The cell density in each PEG–ECM 
hydrogel following 7 days of culture was between 78 and 86% of the initial seeding 
density (Table 3), consistent with PEG hydrogel literature [26, 31, 35, 47, 64-66]. 
Combined, the above data indicate that: (1) each hydrogel formulation maintained an 
osteogenic modulus throughout the study [40] and (2) differences in cell responses 
among formulations can be attributed to differences in the initial proteins tethered to the 
gel network, their interactions with other molecules and subsequent neo-matrix 
deposition. 
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Table 2. Comparison of the average modulus and mesh size of 8 mm discs of each PEG–ECM 
hydrogel formulation with time in culture.
a
 
 
 
 
 
 
 
 
 
a
 Property results represent an average of n = 4 samples for each PEG-ECM formulation 
*
 Significantly different from the corresponding day 0 value, p < 0.05. 
 
 
 
Table 3. Comparison of the average thickness, mass, and cell density in discs of each PEG–ECM 
hydrogel formulation with time in culture.
a
 
 
a 
Results represent an average of n = 4 samples for each PEG–ECM formulation. 
*
 Significantly different from the corresponding day 0 value, p < 0.05. 
 
 
2.4.2. Cell differentiation 
 
Following 7 days of culture, cell differentiation was examined by quantitative 
ELISA or by cell counts (as validated in figure 3). As shown in figure 4, day 7 levels of 
various osteogenic markers indicated significant differences relative to day 0 and/or 
among hydrogel formulations. Specifically, cells in PEG–LN gels expressed 
significantly higher levels of the osteogenic transcription factor osterix than day 0 cells 
(p = 0.032), while osterix expression in PEG–FN gels could not be distinguished from 
Gel type 
Modulus (kPa) Mesh size (µg dextran/g-gel) 
Day 0 Day 7 Day 0 Day 7 
PEG-FN 33.3 ± 0.7 29.2± 0.8
*
 11.8 ± 0.3 12.4± 0.3 
PEG-FG 33.9 ± 1.9 29.9± 1.5
*
 11.4 ± 0.3 11.7± 0.2 
PEG-LN 33.7 ± 2.0 28.7± 1.2
*
 11.6 ± 0.3 11.8± 0.6 
Gel type 
Thickness (mm) Mass of 8mm discs (mg) Cell density (x10
6
) 
Day 0 Day 7 Day 0 Day 7 Day 0 Day 7 
PEG-FN 0.550 ± 0.01 0.560± 0.01 29.1 ± 0.2 29.5± 0.2 1.01± 0.06 0.88± 0.08
* 
PEG-FG 0.550 ± 0.01 0.560± 0.01 29.2 ± 0.2 29.4± 0.5 0.96± 0.05 0.72± 0.02
* 
PEG-LN 0.540 ± 0.01 0.560± 0.01 29.2 ± 0.4 29.3± 0.3 1.01± 0.06 0.82± 0.02
*
 
 26 
 
day 0 levels. In addition, PEG–LN gels retained day 0 osteopontin expression levels, 
whereas osteopontin levels in day 7 PEG–FN gels had fallen to approximately half of 
day 0 levels (p = 0.005). Similarly, day 7  PEG–FN gels contained significantly lower 
levels of the bone ECM protein osteocalcin relative to PEG–FG (p = 0.042) and PEG–
LN (p = 0.002) gels, whereas PEG–FG and PEG–LN gels contained 2.4- and 2.9-fold 
greater osteocalcin levels than day 0 (p = 0.004 and p < 0.001, respectively). 
To assess the specificity of the osteogenic response associated with the PEG–FG 
and PEG–LN gels, mid-term markers of chondrogenesis, smooth muscle progression and 
adipogenesis were evaluated (Figure 5). Day 7 expression of smooth muscle 
transcription factor myocardin was similar to day 0 levels and across hydrogel 
formulations. In addition, day 7 levels of SM22α, a cytoskeletal protein associated with 
smooth muscle differentiation, could also not be distinguished among gel formulations 
or from day 0 levels. PPARγ expression was similar to day 0 levels across the day 7 gels, 
and the day 7 levels of the adipocyte intracellular protein A-FABP were statistically 
indistinguishable from day 0 levels and among formulations. Furthermore, day 7 
expression of chondrogenic transcription factor sox9 did not vary significantly with gel 
formulation or relative to day 0, and day 7 levels of the cartilage-associated ECM protein 
collagen II could also not be distinguished among the PEG–ECM gels or relative to day 
0. Representative immunostaining images for proteins evaluated by cell counts 
(myocardin, PPARγ, and osteopontin) are given in Figure 6.  
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Figure 4. Expression of osteogenic markers osterix, osteopontin and osteocalcin by ELISA (osterix and 
osteocalcin) and cell counts (osteopontin). For ELISA assays, six samples per day 7 formulation were 
analyzed. The day 0 ELISA sample number was n = 4. For cell counts, sections from 4-8 separate samples 
of each formulation were evaluated. Validation of the cell counting assessment method is given in Figure. 
3. For the purpose of comparison, ELISA and cell count measures for each protein have been normalized 
to the corresponding measure for PEG-FN gels.  
*
indicates a significant difference, p < 0.05. 
 
 
2.4.3. Integrin expression 
 
Integrin-associated signaling has been demonstrated to play a key role in MSC 
osteogenic lineage progression [18, 25, 26, 30, 31, 33]. Therefore, initial integrin 
adhesion and temporal alterations in cell integrin profiles were evaluated in order to gain 
insight into the integrin dynamics underlying the observed differentiation results. 
 
2.4.3.1. Initial integrin adhesion 
Inhibition studies were conducted to characterize the integrins through which 
cells initially interacted with the various PEG–ECM hydrogels. As illustrated in Table 4, 
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the day 0 population of 10T½ cells interacted with each PEG–ECM gel via a distinct 
panel of integrins. Specifically, cell adhesion to functionalized FG was inhibited by 
antibodies to αv and α5 integrin subunits, although integrin αv appeared to be dominant. 
In contrast, cell binding to FN was significantly inhibited by antibodies to α2, αv and α5 
integrin subunits, whereas LN interacted with α1, αv, α5 and α6 integrin subunits. 
 
 
Figure 5. (A) Expression of myocardin and SM22α, as assessed by cell counting and ELISA methods, 
respectively. (B) Expression of PPARγ and A-FABP, as assessed by cell counting and ELISA methods, 
respectively. (C) Expression of sox9 and collagen II by ELISA. For ELISA assays, 6–9 samples per day 7 
formulation were analyzed. The day 0 ELISA sample number was n = 4. For cell counts, sections from 
four separate samples of each formulation were evaluated. For the purpose of comparison, ELISA and cell 
count measures for each protein have been normalized to the corresponding measure for PEG–FN gels. 
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Figure 6. Representative images of day 7 immunostaining for myocardin, PPARγ and osteopontin. 
Positive staining is indicated by brown (PPARγ and osteopontin) or red (myocardin) coloration. Scale bar 
= 40 µm and applies to all images. 
 
 
2.4.3.2. Endpoint integrin profiles 
To investigate potential temporal alterations in cell–substrate integrin 
interactions, the endpoint expression of various integrins was investigated relative to day 
0. Day 7 expression of integrin subunits α1, αv and α5 did not significantly vary among 
PEG– ECM gels or relative to day 0 levels (Figure 7). However, integrin α2 expression 
was ~1.6-fold higher in day 7 PEG–LN gels than at day 0 (p = 0.034). Similarly, integrin 
α6 expression in day 7 PEG–FG hydrogels was ~2-fold higher than at day 0 (p = 0.030) 
and was significantly greater than in PEG–FN gels (p = 0.014). Cumulatively, the 
endpoint integrin profiles associated with the PEG–FG and PEG–LN gels differed from 
their initial integrin profiles.  
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Table 4. Percentage inhibition of 10T½ cell adhesion at day 0 by blocking antibodies to various 
integrin alpha subunits.
a
 
 
a 
Integrin inhibition results represent an average of n = 5–10 sample wells per antibody per ECM molecule. 
‘‘–’’ indicates no inhibition detected. 
*
 Significantly different from the corresponding PEG–FN gels, p < 0.05. 
# 
Significantly different from the corresponding PEG–FG gels, p < 0.05. 
 
 
 
Figure 7. Day 7 and day 0 expression of various integrin alpha subunits as assessed by ELISA (n = 6–9 
per day 7 formulation; n = 4 for day 0). For the purpose of comparison, ELISA measures for each protein 
have been normalized to the corresponding measure for PEG–FN gels.  
*
indicates a significant difference, p < 0.05. 
 
 
2.5. DISCUSSION 
 
The aim of the present work was to compare the osteoinductivity of select ECM 
components in defined 3-D environments toward the improved design of osteogenic 
Gel type α1 α2 αv α5 α6 
PEG-FN - 31.9 ± 26.5 52.9 ± 22.8 15.2 ± 5.0 - 
PEG-FG - -
* 
97.5 ± 8.7
*
 2.4 ± 7.7
*
 - 
PEG-LN 31.7 ± 10.7
*,# 
-
* 
24.9± 9.6
# 
26.4 ± 5.9
*,# 
17.0 ± 7.8
*,# 
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scaffolds. These ECM components were examined within the context of scaffolds with 
osteogenic moduli (~30 kPa) [40]. The associated temporal evolution in MSC lineage 
progression and integrin profiles were then characterized. Present data indicated that 
both FG and LN enhanced the osteogenic response of encapsulated 10T½ cells. 
Specifically, osteocalcin levels in day 7 PEG–FG and PEG–LN gels were ~2.4- and 2.9-
fold greater, respectively, than day 0 levels. In addition, expression of osterix, an 
osteoblast-specific transcription factor required for osteogenesis, was significantly 
elevated in day 7 PEG–LN gels relative to day 0 levels. In contrast, the day 7 levels of 
markers for adipogenesis, chondrogenesis and smooth muscle lineage progression were 
not significantly different among formulations or relative to day 0, indicating that the 
osteogenic response associated with the PEG–FG and PEG–LN gels was specific.  
The present results are consistent with previous 2-D studies demonstrating LN to 
support higher active levels of the osteogenic transcription factor Cbfα1 than FN over a 
5 day culture time frame [32]. In addition, a study by Salaszynk et al. indicated that, in 
the absence of osteogenic media supplements, FN did not support human MSC matrix 
mineralization, in contrast to collagen I and vitronectin [26]. Indeed, they found little 
role for FN in stimulating osteogenic differentiation [27], beyond activation of alkaline 
phosphatase [26]. Similarly, Benoit et al. found that FN increased alkaline phosphatase 
production, but not osteopontin gene expression [35]. Although fibrin glue has been used 
extensively in bone tissue engineering [44, 67-76], literature presents conflicting reports 
regarding the osteoinductivity of fibrinogen. Specifically, while several studies have 
suggested that fibrin sealants promote osteogenesis [70, 72-74], other studies have 
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reported negative effects when fibrin sealants were combined with coral granules [75, 
76] and poly(lactide-co-glycolic acid) scaffolds [67]. These conflicting results may arise, 
in part, from differences in the material properties of the various fibrin-containing 
scaffolds assayed. In the present study, we tightly controlled initial scaffold material 
properties as well as the temporal evolution of those properties in order to isolate the 
osteoinductive effect of FG from other matrix properties.  
To gain insight into the origins of the osteogenic response associated with FG 
and LN, we examined the initial integrin-based interactions supported by these ECM 
components. Specifically, integrin blocking studies indicated that day 0 10T½ cells 
interacted with FG primarily through αv integrin subunits. MSC–matrix interactions 
through αv subunits have previously been correlated with osteoinductivity [12, 26]. In 
particular, Salaszynk et al. found that human MSCs bound to vitronectin primarily 
(>90% of adhesive interactions) through αv subunits, and that vitronectin was capable of 
promoting osteogenic differentiation, even in the absence of added growth factors [26]. 
Similarly, Connelly et al. [12] and Yang et al. [48] demonstrated that the peptide RGD, 
which primarily supports αv interactions, promoted expression of osteocalcin. 
In contrast to FG, day 0 10T½ cells bound to FN through integrins α2, αv and αv. 
As with integrin αv, the α2 subunit has been associated with osteogenic differentiation in 
the case of both MSCs [18, 77] and pre-osteoblasts [30]. Specifically, Shih et al. found 
that increased MSC osteogenesis was linked to an increase in integrin α2 expression, and 
that knockdown of integrin α2 downregulated osteogenic differentiation markers [77]. In 
addition, anti-α2 integrin antibody was found to block ascorbic-acid-dependent induction 
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of alkaline phosphatase [34] and of the osteocalcin promoter [30] in MC3T3-E1 pre-
osteoblasts. In contrast to integrin α2, studies involving human MSCs suggest that 
integrin α5 interactions do not support osteogenesis in the absence of osteoinductive 
media supplements [26]. Thus, the reduced osteogenic response associated with PEG–
FN gels may be due, in part, to integrin α5 signaling dominating over or interfering with 
pro-osteogenic integrin α2 and αv signals. That said, it is interesting to note that, in the 
presence of osteogenic media supplements, integrin α5 interactions have been found to 
support osteogenesis [40].  
As for FN, day 0 10T½ interactions with LN were mediated by both integrins αv 
and α5. However, LN also supported significant levels of integrin α1 and α6 interactions 
at day 0. Nevertheless, α1 subunit did not significantly vary among PEG– ECM gels or 
relative to day 0 levels at 1 week of culture. As with integrins α2 and αv, integrin α6 have 
previously been associated with osteogenesis. In particular, integrin α6 upregulation has 
been associated with the MSC osteogenic responses observed on rough titanium surfaces 
[78, 79] and poly(lactide-co-glycolide) constructs [80]. Thus, the osteoinductive effect 
associated with PEG–LN gels may arise, in part, from integrin αv and α6 interactions 
predominating over integrin α5 and α1 interactions.  
The osteoinductive role for integrins α2 and α6 noted in the literature was further 
supported by the temporal variations in integrin profiles observed in the present study. 
Specifically, PEG–FG gels were associated with an increase in integrin α6 expression 
over the time course of the study, and PEG–LN gels were associated with an increase in 
integrin α2 expression. The increased expression of these integrin subunits may therefore 
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have contributed to the osteogenic effects of both the PEG–LN and PEG–FG gels, 
although definitive statements cannot be made since the presence of a specific integrin 
does not necessarily imply its activity.  
Several limitations of the present study merit comment. FG, FN and LN each 
support an array of interactions, such as cytokine and ECM protein binding, which likely 
influenced both integrin-mediated and non-integrin-mediated cell–hydrogel interactions. 
In addition, non-integrin cell–ECM interactions associated with deposited neo-matrix 
were not assessed. Thus, the present interpretations linking osteogenic responses to 
particular integrins must be treated with caution. In particular, further studies would be 
required to establish potential causative relationships between observed cell responses 
and associated integrin profiles. Finally, osteogenesis represents a complex set of 
processes that are mediated by a number of factors. The interplay between these factors 
and the precise sequences leading to osteogenic commitment are not fully understood, 
and the present study examined only a limited subset of the interactions and a limited 
panel of the markers that characterize osteogenesis. Furthermore, the present results do 
not enable the impact of the 3-D culture environment itself to be assessed.  
Despite the limitations discussed previously, the cumulative ECM and 
phenotypic data indicate that LN may be the most appropriate of the biomolecules 
examined for promoting specific osteogenic differentiation within the context of 
scaffolds with osteoinductive moduli. Future studies will focus on exploring a broader 
range of time points and ECM protein concentrations as well as on examining potential 
synergy between various ECM components. 
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CHAPTER III 
NOVEL COLLAGEN-MIMETIC PROTEINS FOR THE FABRICATION OF HYBRID 
POLYMERIC SCAFFOLDS
*
 
 
3.1. OVERVIEW 
 
The results from the studies described in chapter II indicated that FG and LN 
enhanced the osteogenic response of encapsulated 10T½ cells. Moreover, integrin α2 and 
α6 appeared to have played an important role in MSC osteogenic differentiation. 
Nonetheless, native biomolecules such as FG, FN and LN also support an array of 
additional signals which guide cell behavior. These signals include alternate cell 
adhesion sites, enzyme cleavage sequences, as well as growth factor and cytokine 
binding regions. These intricate biological interactions make it difficult to deconvolute 
the impact of integrin-based interactions on associated cellular signaling. Consequently, 
the results from the previous study cannot be definitively linked to integrin α2 and α6 
signaling.  
 
 
                                                 
*
 Part of this chapter is reprinted with permission from ““Bioactive hydrogels based on Designer 
Collagens” by Cosgriff-Hernandez E, Hahn MS, Russell B, Wilems T, Munoz-Pinto D, Browning MB, 
Rivera J, Höök M, 2010. Acta Biomaterialia, 6, 3969-3977, Copyright [2010] by Acta Materialia Inc. 
Published by Elsevier Ltd. 
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We therefore propose to investigate the impact of integrin α2 binding sequence 
and compare it to integrin α1, which appeared to be not correlated with osteogenesis, in a 
more controlled format. Toward this goal, a class of collagen-mimetic proteins was used. 
These collagen-mimetic proteins are based on streptococcal collagen-like (Scl2) proteins 
that form a triple helix similar to mammalian collagens. In contrast to the numerous cell-
binding sites on collagen, Scl2 from Streptococcus pyogenes serotype M28 does not 
contain any known cell-binding sites and thus provides a blank slate in terms of cellular 
interactions. In the current study, Scl2 protein was modified to include receptor binding 
motifs that interact with α1 and or α2 integrin subunits. 
Despite the potential of these Scl2 proteins in several applications, the utility of 
this recombinant protein family is currently limited to coatings due to the inability of 
Scl2 proteins to assemble into stable three-dimensional networks. To address this 
limitation, the Scl2 proteins were functionalized with photocrosslinking sites to enable 
incorporation into a hydrogel matrix. Characterization studies confirmed that the 
functionalization of the Scl2 proteins did not disrupt triple helix conformation, integrin 
binding or cell adhesion. Bioactive hydrogels were fabricated by combining the 
functionalized Scl2 proteins with poly(ethylene glycol) diacrylate (PEGDA) and 
photocrosslinking. Finally, human mesenchymal stem cell adhesion studies confirmed 
both cell-specific adhesion and appropriate activation of different MAP kinase signaling 
pathways due to selective integrin binding to the two receptor binding motifs 
investigated. These results serve to highlight the potential of this novel biomaterial 
platform in the development of improved scaffolds. 
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3.2. INTRODUCTION 
 
The extracellular matrix (ECM), a complex network which is mainly composed 
of insoluble biomolecules, soluble biomolecules, and proteins and other factors from 
cell-cell interactions, is fundamental for essential biological processes such as cell 
migration, morphogenesis, cell proliferation, apoptosis, organogenesis and cell 
differentiation [81-83]. One of the biomolecules that compose the ECM is collagen. 
Collagens are a family of proteins that serve as structural building blocks of mammalian 
tissues [81, 84, 85]. Additionally, collagens have the ability to interact with specific 
cellular receptors, such as integrins [86, 87]. Integrins, which are considered 
transmembrane receptors, are large glycoproteins composed of α and β subunits [81, 87-
90]. Up to now, 18 and 8 different α and β subunits, respectively, have been identified 
which can noncovalently combine to form 24 different heterodimers with distinct 
specificities [81, 90, 91]. For instance, α2β1, α10β1, and α11β1 integrins are known to 
mediate interactions between several collagen types and the ECM [92, 93]. Integrin-
ECM interactions impact cell behavior by the activation of the focal adhesion kinase 
(FAK) [94, 95]. Activated FAK triggers activation of mitogen-activated protein kinases 
(MAPKs) as is shown in Figure 8. To date, different groups of MAP kinases have been 
discovered to be involved in signaling cascades. These groups include signal-regulated 
kinases (ERKs) 1 and 2 (ERK1/2); 1, 2, and 3, p38 isoforms α, β, γ, and δ; c-Jun amino-
terminal (JNK) [96-98]. Nevertheless, the most studied MAP kinases are the ERK1/2 
and p38α kinases.  
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Figure 8. Schematic outline showing the activation of different MAP kinase pathways by the 
phosphorylation of FAK.  
Adapted from [99] 
 
 
In attributing mesenchymal stem cell osteogenesis to binding of a particular 
integrin requires that control over these and surrounding (non-integrin) interactions. This 
is a level of control that native biomolecules, such as collagen, cannot provide. In 
addition, the signaling associated with these specific integrin interactions must be 
characterized. Collagen-mimetic proteins are a novel protein family recently generated 
from streptococcal collagen-like (Scl2) proteins, isolated from group A Streptococcus. 
Expression of these proteins in bacterial culture enables a level of batch consistency and 
economies of scale not possible with solid-phase synthesis or native collagen extraction 
[85, 87, 100]. The unhydroxylated Scl2 proteins contain the GXY repeats associated 
with mammalian collagen but are able to form a stable triple helix at physiological 
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temperature in the absence of further modification [87, 101]. This is in contrast to 
recombinantly expressed human collagens, which require expensive post-translational 
modification to achieve the native triple helical conformation. Furthermore, whereas 
native collagen contains numerous binding sites that interact with integrins expressed by 
a wide range of cells, the Scl2 protein (scl2.28 from the serotype M28 strain 
MGAS6274A) functions as a biological blank slate [102-105]. Site-directed mutagenesis 
has been successfully utilized to insert specific receptor binding motifs into the Scl2 
protein to promote cell adhesion, spreading, and migration [106]. Thus, specific 
mutations can be used to control the cell–material interactions of these recombinant 
proteins, and the Scl2 protein may be designed to induce selective cell adhesion and 
function.  
In the present study, Scl2 proteins modified to contain the peptide sequences 
GFPGER or GFPGEN were selected for examination. These receptor binding motifs 
were based on the previously characterized GF/LOGER sequence (O; hydroxyproline), 
which interacts with collagen-binding α1 and α2 integrin I-domains [20, 107-109], and on 
molecular modeling of different collagen sequences in complex with α1 and α2 integrin I-
domains. The Scl2 proteins modified to contain these integrin binding sequences have 
previously been shown to support cell-specific binding and spreading and migration 
[106]. However, unlike native fibrillar collagens, Scl2 proteins do not form stable 
networks and are limited to coating applications. 
To use these proteins to examine the impact of specific integrin signaling on 
osteogenesis, the Scl2 proteins needed to be assembled into stable 3D structures. In 
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addition, the capacity of mesenchymal stem cells to bind to these proteins with 
stimulation of appropriate cellular signaling had to be demonstrated. In the current study, 
the Scl2 proteins were functionalized with photocrosslinking sites to enable 
incorporation into a three-dimensional (3-D) hydrogel matrix. Characterization studies 
were performed to investigate the effect of functionalization on the triple helix 
conformation, integrin binding and cell adhesion of the modified Scl2 proteins. Also, 
human mesenchymal stem adhesion studies were conducted to confirm both cell-specific 
adhesion and appropriate activation of different MAP kinase signaling pathways due to 
selective integrin binding to the two receptor binding motifs. Subsequent conjugation of 
Scl2 protein within a synthetic PEGDA network was then utilized to examine the impact 
of different Scl2s on cell adhesion and ascertain the potential of these materials in the 
future development of bioactive scaffolds. 
 
3.3. MATERIALS AND METHODS 
 
3.3.1. Materials 
 
All chemicals were used as received. Poly(ethylene glycol)-acrylate-N-
hydroxysuccinimide (3400 g mol
-1
) (Ac-PEG-NHS) was purchased from JenKem 
Technology (Allen, Texas). All other chemicals were purchased from Sigma Aldrich 
(Milwaukee, WI). Recombinant α1 I-domains were expressed in E. coli BL21 and 
purified as described previously [20]. Recombinant proteins were dialyzed against 
 41 
 
phosphate-buffered saline (PBS), pH 7.4 and protein concentrations were determined 
using a calculated extinction coefficient for each protein. 
 
3.3.2. Collagen-mimetic proteins based on streptococcal collagen-like protein (Scl2)  
 
The scl2.28 sequence was amplified from the serotype M28 strain MGAS6274A (Scl2-
1) and purified as previously described [87]. Scl2-1 served as the negative control as it 
does not contain binding sites for α1β1 or α2β2 and has previously been shown to be non-
adhesive [85, 102-106]. Variants of this protein containing the sequence GFPGER (Scl2-
2) or GFPGEN (Scl2-3) were generated by single amino acid mutations introduced in 
Scl2-1 using synthesized PCR primers (Integrated DNA Technologies) and the 
QuikChange site-directed mutagenesis kit per the manufacturer’s instructions 
(Stratagene) (Figure 9). The mutations were verified by sequencing (SeqWright, 
Houston, TX). Recombinant proteins were expressed using standard recombinant protein 
procedures in E. coli BL21 (Novagen) and purified by affinity chromatography on a 
StrepTrap HP column (GE Healthcare). Protein purity was determined by SDS-PAGE 
followed by coomassie blue staining. Proteins were stored at 4°C in PBS (pH 7.4) until 
use. 
 
3.3.3. Scl2 conjugation to PEG linker with photoreactive crosslinks 
 
Scl2   proteins   and   a   rat   tail   collagen   I   control   (Sigma   Aldrich)   were  
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functionalized with photoreactive crosslink sites to enable hydrogel formation according 
to a protocol adapted from Sebra et al. (Figure 10) [110]. Scl2 proteins contain ~9% 
lysine groups that readily facilitate bioconjugation chemistry via the established NHS - 
lysine ε−amino group reaction. Briefly, Scl2s were reacted with acrylate-PEG-N-
Hydroxysuccinimide (Ac-PEG-NHS, MW 2000) in 50 mM sodium bicarbonate buffer 
(pH 8.5) at room temperature. A molar ratio of 2:1 Ac-PEG-NHS:NH2 was used and the 
reaction was allowed to proceed for 18 h at room temperature with shaking. Excess Ac-
PEG-NHS and other reaction byproducts were removed via dialysis (MWCO = 20,000). 
Functionalization of the modified proteins (Collagen-F, Scl2-F) was confirmed with 
infrared (IR) spectroscopy and gel electrophoresis (data not shown). 
 
 
Figure 9. Schematic representation of the site-directed mutagenesis of Scl2 to create Scl2-2 and Scl2-3 
with integrin binding motifs. PCR primers were used to generate the integrin binding sequences 
GX1Y1GX2Y2. 
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Figure 10: Schematic representation of the functionalization of Scl2 proteins with photoreactive 
crosslink sites to enable hydrogel formation. An image of a PEGDA-Scl2 hydrogel and schematic of the 
associated hydrogel network structure are provided. 
 
 
3.3.4. Characterization of integrin specificity of functionalized Scl2 proteins 
 
An   enzyme-linked  immunosorbant  assay  ELISA)  was  utilized  to  assess  the  
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specificity of recombinant α1 I-domain binding to control and functionalized Scl2 
proteins. Microtiter wells were coated with 1 µg per well of Scl2-1, Scl2-2, Scl2-3, or rat 
tail derived collagen type I (Cultrex R&D) in PBS containing 1 mM MgCl2 or 1 mM 
EDTA overnight at 4°C. The samples were blocked with PBS containing 1% BSA (w/v) 
for 1 h at room temperature. Five µM α1 I-domains (0.12 mg ml
-1
) were added to the 
wells and incubated for 2 h at room temperature. A mouse monoclonal anti-His-HRP 
conjugate (Alpha Diagnostics) followed by SigmaFast OPD (Sigma) incubation at 1 h 
was used to detect bound I-domains. The absorbance at 450 nm was measured using a 
Thermomax plate reader (Molecular Devices Corp, Menlo Park, CA). Experiments were 
performed in triplicate. 
To confirm that each Scl2 protein retained appropriate cell interactions following 
conjugation to PEG, the ability of three distinct cell populations to interact with the 
functionalized proteins was examined in two dimension (2D): (1) C2C12 cells, which do 
not natively express α1 and α2 integrin subunits; (2) C2C12 cells modified to stably 
express human α1 integrin subunits (C2C12-α1); and (3) C2C12 cells modified to stably 
express human α2 integrin subunits (C2C12-α2). Mouse myoblast C2C12, C2C12-α1, and 
C2C12-α2 cells were kindly provided by Dr. Donald Gullberg (University of Bergen, 
Bergen, Norway) and maintained in DMEM with 10% FBS (Hyclone) supplemented 
with no antibiotic, 1 mg ml
-1
 geneticin (Invitrogen), or 10 µg ml
-1
 of puromycin 
(InvivoGen), respectively. The expression of α1 or α2, and β1 integrin subunits on the 
surface of the modified C2C12 cells was confirmed by immunocytochemistry prior to 
cell culture studies (data not shown). 
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3.3.5. Cell adhesion to functionalized Scl2 proteins 
 
For cell adhesion studies, microtiter plates were coated with functionalized and 
unmodified Scl2-1, Scl2-2, and Scl2-3. Rat tail collagen I coated wells served as positive 
controls. Microtiter wells were coated with 1 µg per well of Scl2 1, Scl2-2, Scl2-3, or rat 
tail derived collagen type I (Cultrex R&D) in PBS overnight at 4°C. The Scl2 protein 
solutions were filter-sterilized using a 0.22 µm PDVF membrane (Millipore) prior to 
application to the microtiter plate. For each Scl2 protein, 15 wells (3 wells per cell type 
examined) were coated. After blocking with PBS containing 1% BSA for 1 h, the wells 
were rinsed extensively with PBS and cells were seeded onto the coated surfaces at 
6,000 cells cm
-2
.  
Prior to seeding, cells were adapted to serum free media (DMEM containing 
1mM CaCl2 and 1mM MgCl2) for 3 h, after which cells were harvested by brief 
exposure to 0.125% trypsin (Mediatech) and resuspended in serum free media 
supplemented with 0.2% BSA. Following 3 h exposure to the coated surfaces at 37 °C / 
5% CO2, cells were fixed with 4 % paraformaldehyde and stained with rhodamine 
phalloidin (Invitrogen) and SybrGreen (Invitrogen). Rhodamine- labeled phalloidin in 
combination with SybrGreen were chosen as cell markers because phalloidin binds to F-
actin, which is present in abundance in cell cytoplasm, and SybrGreen binds DNA, 
which indicates the location of the nucleus of each cell. Representative fluorescence 
images were obtained using a Zeiss Axiovert microscope.  
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3.3.6 Cell chip studies 
 
Agilent 2100 analyzer and the Cell Fluorescence LabChip
®
Kit (Agilent) were 
used to characterize integrin specificity of human mesenchymal stem cells (hMSCs). 
hMSCs (approximately 0.4 million per staining) were collected and washed with cold D-
PBS (Gibco) once and resuspended in staining buffer (PBS supplemented with 1% BSA) 
to reach 2 million cells ml
-1
. 2 µM Calcein solution (Molecular Probes) was used to stain 
the live cells for 30 minutes at room temperature and protected from light. Before 
applying the primary antibody, cells were washed twice with staining buffer. Integrin α1, 
integrin α2, and appropriate positive and negative controls were used to perform the 
staining. Specifically, 1µg of each primary antibody and appropriate isotype controls 
IgG diluted in staining buffer was used. Further details on antibodies are given in Table 
5. All samples were incubated on ice for 30 minutes protecting from light. Subsequently, 
cells were washed twice with staining buffer, and fluorescence-labeled secondary 
antibodies (Jackson Immunoresearch) were added to the cell suspension in order to label 
the cells using a 1:50 dilution in staining buffer. Cell suspensions were incubated on ice 
for 30 minutes protecting from light. Labeled cells were spun down and resuspended in 
80ul of cell buffer (Cell Fluorescence LabChip
®
Kit, Agilent) and 10ul of sample were 
loaded onto the cell chip per manufacturer’s protocol.  
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Table 5. Antibodies employed in cell chip and western blot assays. 
Antibody Clone Supplier Cell chip Western blot 
Integrin α1 FB12 MP   
Integrin α2 P1E6 MP   
CD105 MJ7/18 SCBT   
FAK C-20 SCBT   
p-FAK Tyr 397 MP   
ERK1 K-23 SCBT   
p-ERK1/2 12E4 SCBT   
p38α F-9 SCBT   
p-p38 Thr 180/ Tyr 182 SCBT   
 
†
Abbreviations: MP – Millipore; SCBT – Santa Cruz Biotechnology 
 
 
3.3.7. Human mesenchymal stem cell adhesion to functionalized Scl2 proteins 
 
To assess the ability of hMSCs to interact with the functionalized proteins, cell 
adhesion was examined in two dimensions (2D). The expression of α1 and α2 integrin 
subunits on the surface of the hMSCs was confirmed by flow cytometry, as described 
previously, prior to cell culture studies. Cryopreserved hMSCs (Lonza) at passage 2 
were thawed and expanded in monolayer culture per Lonza protocols. Prior to seeding, 
cells were maintained at 37 ºC and 5% CO2 in MesenPRO RS
TM
 Media (Gibco) 
supplemented with 2% MesenPRO RS
TM
 growth supplement (Gibco). Cell adhesion 
studies were performed following the procedure previously described in 3.3.5.  
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3.3.8. Cell signaling studies 
 
To further study the interaction between hMSCs and Scl2 proteins, the activation 
of important cell signaling pathways was investigated. Cryopreserved hMSCs (Lonza) at 
passage 2 were thawed and expanded in monolayer culture per Lonza protocols. Prior to 
seeding, cells were maintained at 37 ºC and 5% CO2 in MesenPRO RS
TM
 Media (Gibco) 
supplemented with 2% MesenPRO RS
TM
 growth supplement (Gibco). In brief, 12-well 
plates were coated with Scl2-1, Scl2-2, and Scl2-3 proteins. Proteins were resuspended 
in PBS at 100 μg mL-1, and 1 ml well-1 of protein solution was applied and incubated 
overnight at 4 °C. The Scl2 protein solutions were filter-sterilized using a 0.22 µm 
PDVF membrane (Millipore) prior to application to the 12-well plate. Harvested hMSCs 
were washed with PBS and resuspended in serum-free DMEM (Gibco). The cell 
suspensions were subsequently applied to the coated wells at 10,000 cells cm
-2
. 
Prior to seeding, cells were adapted to serum free media (DMEM ) overnight, 
after which cells were harvested by exposure to 3mM EDTA solution in PBS, pH. 7.4. 
Cells were resuspended in serum free media and maintained in suspension for 1 h at 
room temperature. Following 30 min exposure to the coated surfaces at 37 °C / 5% CO2, 
cells were lysed with cell extraction buffer supplemented with protease and phosphate 
inhibitors (1% Triton, 0.1% SDS, 10 mM sodium fluoride, 1 mM sodium pyrophosphate, 
2 mM sodium orthovanadate, 1x protease cocktail (Thermo Scientific) in PBS) for 30 
minutes at 4 °C. Protein levels of the resulting lysates were measured by the Bio-Rad 
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DC protein assay. The activation of FAK, ERK1/2 and p38α MAP kinases was 
evaluated using western blots.  
 
3.3.9. Western blot assays 
 
For Western blot assays, equal amounts of protein (10 µg per lane) were loaded 
into different wells of a 10% polyacrylamide gel and proteins were separated by 
electrophoresis. Before loading the samples onto the gel, protein solutions were 
concentrated using 3,000 MWCO Amicon filter units (Millipore), following denaturing 
by addition of β-mercaptoethanol solution and heating at 100 °C for 10 minutes. After 
electrophoresis, proteins were transferred to a nitrocellulose membrane (Thermo 
Scientific). The blot was cut into two parts and washed twice with double deionized 
water for 5 minutes each time at room temperature. The blots were then blocked with a 
5% BSA solution (Fraction V, Fisher Scientific) in Tris-buffered saline containing 0.1% 
Tween-20 (TBST; 25 mM Tris-HCl, pH. 7.5, 137 mM NaCl, 0.1% Tween 20) for 1 hour 
at room temperature. Following blocking incubation, blots were briefly rinsed with 
TBST. Each blot was incubated with the appropriate primary antibody diluted in TBST 
solution containing 5% BSA overnight at 4 °C. Further details on antibodies employed 
for this study can be found in Table 5. After washing three times with TBST solution, 
primary antibody bound to each blot was detected using an appropriate HRP or AP 
conjugated secondary antibody (Jackson Immunoresearch) diluted in TBST solution 
containing 5% BSA for 1 h at room temperature. Blots were further washed three times 
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with TBST solution, 5 minutes each time, at room temperature.  Signal was detected 
using a luminol reagent (SCBT) or AP chemiluminescent solution (Novex). Imaging was 
performed using the molecular imager chemidoc XRS system (Biorad) and band 
intensity was quantified using Adobe Phothoshop. 
 
3.3.10. Preparation of biologically active PEG-Scl2 hydrogels 
 
PEGDA was synthesized by adding acryloyl chloride dropwise to a solution of 
PEG (3.4 kDa, Fluka) and triethylamine in anhydrous dichloromethane (DCM) under an 
argon blanket. The molar ratio of diester, acryloyl chloride, and triethylamine was 
1:2.5:2.1, respectively. The reaction was maintained at low temperature to reduce 
undesired side reactions utilizing a salt/ice bath. After the addition of acryloyl chloride, 
the reaction was stirred overnight. The resulting solution was washed with 2 M K2CO3 to 
remove acidic byproducts. The DCM phase was subsequently dried with anhydrous 
MgSO4, and the PEGDA product was then precipitated in diethyl ether, filtered, and 
dried under vacuum. Acrylation of the PEG end hydroxyl groups was characterized by 
proton nuclear magnetic resonance (
1
H-NMR) to be ~85%. 
The ability of Scl2-2F and Scl2-3F proteins to mediate cell adhesion following 
incorporation within PEGDA hydrogels 3D networks was also examined. Scl2-F and 
Collagen-F proteins were dissolved at 6 mg protein ml
-1
 in 20 mM acetic acid. PEGDA 
powder was then added to each solution to 5 wt%, followed by the addition of 10 µL 
mL
-1
 of a 300 mg ml
-1
 solution of UV photoinitiator 2,2-dimethoxy-2-phenyl-
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acetophenone in N-vinylpyrrolidone. The resulting solutions were sterile-filtered, 
pipetted between glass plates separated by 200 µm spacers (cell studies) or 1 mm spacers 
(mechanical testing), and polymerized by 10 min exposure to longwave UV light (~ 6 
mW cm
-2
, Spectroline).  
The resulting hydrogels were immersed in PBS for 24 h, after which a set of 8 
mm punches were collected from the swollen gels. Punches from hydrogels reserved for 
mechanical testing were measured using a digital caliper. Following application of a 
0.05 N preload, each hydrogel was subjected to compression at a rate of 6 mm min
-1
 
using an Instron 3342. The compressive modulus of each hydrogel formulation was 
extracted from the resulting stress-strain data. For cell adhesion studies, C2C12, C2C12-
α1, and C2C12-α2 were harvested, resuspended in media containing 10% FBS, and 
seeded onto the swollen Scl2-containing gels at 10,000-20,000 cell cm
-2
. After 3 h at 37 
°C / 5% CO2, cells were fixed with paraformaldehyde and stained with rhodamine 
phalloidin and SybrGreen. Representative fluorescence images were obtained using a 
Zeiss Axiovert microscope. Rat tail collagen I-containing hydrogels served as positive 
controls. 
 
3.3.11. Statistical analyses 
 
Data are reported as mean ± standard deviation. Comparison of sample means 
was performed by ANOVA followed by Tukey’s post hoc test (SPSS software), p < 
0.05. 
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3.4. RESULTS AND DISCUSSION 
 
The present study was designed to extend the potential utility of Scl2 proteins in 
tissue engineering applications by functionalizing specific Scl2 proteins to permit their 
conjugation into PEGDA hydrogel networks. Toward this goal, the ability to 
functionalize Scl2 without disrupting the native conformation, integrin binding affinity, 
appropriate cell signaling and cell interactions of Scl2 proteins was examined. 
 
3.4.1. Confirmation of Scl2 functionalization  
 
The functionalized Scl2 proteins, denoted Scl2-F, were first analyzed using IR 
spectroscopy. IR absorbance peaks assigned to the peptide (amide, C=O) at 1630 cm
-1
 
and PEG (ether, C-O-C) at 1110 cm
-1
 were both present in the purified product (data not 
shown). Control experiments confirmed that non-bonded PEG was removed by dialysis 
over the selected time period (data not shown); thus, the presence of PEG in the product 
was concluded to be coupled to the Scl2 and collagen control. As an additional 
confirmation of functionalization, collagen and Scl2 peptides exposed to Ac-PEG-NHS 
were heat denatured and run on a native SDS-PAGE gel. SDS-PAGE is a 
straightforward method of monitoring the PEGylation of proteins because the grafting of 
PEG has a detectable effect on the mobility of the protein in acrylamide gels [111-113]. 
The smeared bands associated with the products as compared to the unmodified controls 
confirmed conjugation and reflect the polydispersity of the products (Figure 11).  
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Figure 11. Coomassie-stained 12% SDS–PAGE analysis of functionalized Scl2 proteins (Scl2-1 Control, 
Scl2-1F, Scl2-2F, Scl2-3F) with and without heat denaturation. 
 
 
3.4.2. Maintenance of triple helical structure and bioactivity following PEGylation  
 
Extensive protein functionalization has been shown in some cases to disrupt 
protein conformation and adhesion site availability [114]. It was therefore important to 
confirm that Scl2-F proteins retained their triple helical conformation and biological 
activity. Scl2-F proteins ran as homogeneous trimers, with an estimated molecular 
weight of ~120 kDa, under non-denaturing electrophoretic conditions, in comparison to 
their heat-denatured counterparts, which exhibited molecular masses of ~35 kDa (Figure 
11).  
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Retention of expected bioactivity was qualitatively evaluated by solid phase 
binding assays. Microtiter wells were coated with Scl2-1, Scl2-2, Scl2-3, Scl2-1F, Scl2-
2F, Scl2-3F, or collagen type I and exposed to recombinant human α1 integrin I-
domains. As expected, Scl2-1 bound minimal and collagen type I exhibited maximal α1 
integrin I-domain binding levels (Figure 12). Furthermore, Scl2-2, containing the 
GFPGER integrin adhesion sequence, and Scl2-3, containing the GFPGEN integrin 
adhesion sequence, bound α1 integrin I-domain at levels intermediate between collagen I 
and Scl2-1. Similar trends were observed with the Scl2-F proteins, which indicated that 
appropriate integrin binding was retained on functionalization. A modest decrease was 
observed between the functionalized and non-functionalized proteins; however, this 
difference was not statistically significant. 
 
 
Figure 12. Microtiter plates were coated with Scl2s and functionalized Scl2s at a concentration of 1 mg 
per well. Recombinant α1 integrin I-binding domains (5 mM) were allowed to adhere for 2 hours and 
ELISA performed to quantify integrin binding.   
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3.4.3. Cell adhesion to functionalized Scl2 proteins 
 
As previously discussed, the receptor binding motifs GFRGER and GFPGEN 
were selected for examination based on the previously characterized GF/LOGER 
sequence [20, 107-109] and on molecular modeling of different collagen sequences in 
complex with α1 and α2 integrin I-domains. To confirm that cells could recognize and 
bind these integrin binding motifs in Scl2-F proteins, cell adhesion and spreading studies 
were performed using mouse C2C12 cells or stably transfected cell lines expressing the 
human integrin α1 subunit, C2C12-α1, or the human integrin α2 subunit, C2C12-α2. Since 
C2C12 cells do not normally express collagen-binding α1 or α2 integrins, comparison of 
the binding of unmodified C2C12 cells with that of C2C12-α1 and C2C12-α2 could be 
utilized to evaluate the extent to which observed cell adhesion to Scl2-2F and Scl2-3F 
was due exclusively to α1 or α2 integrin mediated interactions.   
C2C12, C2C12-α1, or C2C12-α2 cells were allowed to adhere and spread for 3 h 
on microtiter plates coated with 1 µg protein per well. As anticipated, Scl2-1F coated 
surfaces displayed similar cell adhesion and spreading as BSA-coated negative controls. 
Scl2-2F and Scl2-3F induced spreading of C2C12-α1 (Figure 13, second column), as did 
the collagen-F positive control. In contrast, C2C12-α2 cells (Figure 13, third column) 
adhered and spread on Scl2-2F and collagen-F but not on Scl2-3F while unmodified 
C2C12 cells were unable to significantly adhere to either Scl2-2F or Scl2-3F. 
Cumulatively, these cell adhesion results indicate that 1) Scl2-2F and Scl2-3F mediate 
cell adhesion via binding to α1 and or α2 integrins (C2C12 results), 2) Scl2-2F interacts 
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with both α1 and α2 integrins (C2C12-α1 and C2C12-α2 results), and 3) Scl2-3F binds 
only α1 integrins (C2C12-α1 and C2C12-α2 results), consistent with the expected integrin 
binding of each protein. 
 
 
Figure 13. High binding polystyrene 96 well plates were coated with Scl2-1F, Scl2-2F, Scl2-3F, and 
functionalized type I collagen (collagen-F) at 1 µg protein per well. Unmodified C2C12 cells, C2C12-α1 
cells, C2C12-α2 were seeded at a density of 6,000 cells cm-2 and allowed to spread for 3 hours. Attached 
cells were fixed with 4% paraformaldehyde, stained with rhodamine phalloidin (F-actin) and SybrGreen 
(nucleus), and imaged by fluorescence microscopy. Large circles in the Scl2-1 images are a result of 
floating, non-adherent cells outside of the focal plane Scale bar applies to all images and equals 100 µm.  
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3.4.4. Scl2 proteins promote hMSC adhesion and appropriate intracellular signaling 
 
To assess the ability of hMSCs to interact with the Scl2 functionalized proteins, 
cell adhesion was examined in two dimensions (2D). First, integrin expression levels in 
hMSCs were analyzed using a cell fluid-based microchip, whose working principle is 
similar to that of flow cytometry [115]. hMSCs were stained using specific antibodies 
for integrin α1 and integrin α2 since adhesion to the Scl2 proteins is mediated by these 
two integrin subunits. Appropriate negative and positive controls were used, and 
fluorescently-labeled secondary antibodies were employed for the detection of primary 
antibody binding. As shown in Figure 14, hMSCs stained positive for both integrin α1 
and integrin α2 subunits. However, integrin α2 expression was higher (~90%) compared 
to integrin α1 expression (~55%).  
On the other hand, hMSC attachment and spreading was also investigated 
(Figure 15). hMSCs strongly spread on collagen-F coated surfaces (data not shown). 
Furthermore, Scl2-2F and Scl2-3F coated surfaces mediated hMSC attachment and 
spreading whereas hMSC adhesion on Scl2-1F coated wells was minimal. Compared to 
Scl2-3F samples, hMSC spreading was higher in Scl2-2F coated surfaces. Therefore, 
Scl2-2F and Scl2-3F appeared to selectively mediate the attachment and spreading of 
hMSC. Cumulatively, these cell adhesion and cell fluid-based microchip studies suggest 
that: 1) the selectivity of hMSC adhesion to the Scl2 proteins may be due to the 
differences in α1 and α2 integrin expression, 2) hMSC adhesion to Scl2-2F coated 
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surfaces occurs through α1 and α2 integrin subunits, and 3) hMSC α1 integrin expression 
mediates binding to Scl2-3F coated surfaces.  
 
 
Figure 14. Integrin α1 and α2 characterization of hMSCs by cell chip based flow cytometry. A) Single 
parameter histograms showed the relative fluorescence intensity of staining and the cell counts. B) Isotype 
control was used to set up the gate in order to calculate the positive cells that were stained for each integrin 
(data not shown). 
 
 
To further investigate the interactions between hMSCs and Scl2 proteins, the 
activation of important cell signaling pathways involved in cell adhesion was studied. 
Mitogen-activated protein kinases (MAPKs) play a fundamental role in the regulation of 
gene expression, cell adhesion, cell motility and cell differentiation [116]. In addition, it 
has been shown  that cell adhesion is  mediated by integrin signaling events  that involve 
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Figure 15. High binding polystyrene 96 well plates were coated with Scl2-1F, Scl2-2F and Scl2-3F at 1 
µg protein per well. hMSCs were seeded at a density of 6,000 cells cm
-2
 and allowed to spread for 3 hours. 
Attached cells were fixed with 4% paraformaldehyde, stained with rhodamine phalloidin (F-actin) and 
SybrGreen (nucleus), and imaged by fluorescence microscopy. Scale bar applies to all images and equals 
100 µm. 
 
 
the phosphorylation of focal adhesion kinase (FAK), which initiates signaling through 
multiple intracellular MAP kinase pathways such as ERK1/2 and p38 [117-119]. 
Therefore, phosphorylation and activation of these two pathways was investigated. As a 
result, hMSCs were allowed to adhere for 30 minutes (time required for FAK activation 
[120-122]) on 12-well plates coated with 10 µg protein per well. Afterwards, cells were 
lysed and lysates were prepared and analyzed through immunoblotting with 
phosphorylated site-specific primary antibodies directed against TYR 397 FAK, 
T202/Y204 ERK and T180/Y182 p38. The respective total proteins (FAK, ERK and 
p38) were also analyzed using immunoblots. Band intensities were computed, and the 
activated fraction of each MAP kinase protein under study was calculated by dividing 
the band intensity of the phosphorylated protein by the respective band intensity of total 
protein. As illustrated in Table 6, a significant increase in the activated fraction of FAK, 
ERK1/2 and p38 was observed for Scl2-2 and Scl2-3 samples relative to Scl2-1. 
Comparison of activation levels between Scl2-2 and Scl2-3 indicates that 
phosphorylation of FAK and p38 was significantly lower in response to adhesion onto 
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Scl2-3 relative to Scl2-2 coated surfaces. Specifically, the active fractions of FAK and 
p38 for Scl2-2 were ~1.17 and 1.25 greater than those for Scl2-3, respectively. Likewise, 
ERK1/2 activation was apparently lower in Scl2-3 relative to Scl2-2; however, a 
significant difference was not observed. Cumulatively, the present data associated with 
MAP kinase signaling suggests that 1) integrin α1 and integrin α2 dependent adhesion to 
Scl2-2 and Scl2-3 enhanced the activation of FAK, ERK1/2 and p38 proteins, 2) Scl2-2 
had a higher effect in MAP kinase-associated protein phosphorylation compared to Scl2-
3, and 3) protein activation in Scl2-2 samples was the most enhanced for FAK and p38, 
relative to ERK1/2. Thus, activation of FAK and p38 pathways might be related to cell 
adhesion interactions through integrin α2 subunit. 
 
Table 6. Activated fraction of each of the MAP kinase proteins that was investigated. Data of 
Scl2-1 was used for normalization. 
 
 
 
 
 
 
 
 
*
 Significantly different from the corresponding Scl2-1, p < 0.05. 
# 
Significantly different from the corresponding Scl2-2 gels, p < 0.05. 
 
 
3.4.5. Bioactive hydrogels with cell-specific adhesion 
 
Scl2-F proteins were conjugated within 5 wt% PEGDA hydrogels resulting in 
stable three dimensional gel networks (Figure 10). PEGDA was selected as the base-
material for the hydrogel network due to the broad tunability of PEG gel mechanical 
Protein type pFAK/FAK pERK/ERK pp38/p38 
Scl2-1 1.00 ± 0.11 1.00 ± 0.04 1.00 ± 0.05 
Scl2-2 1.64± 0.05
*
 1.18 ± 0.03
* 
1.17 ± 0.04
*
 
Scl2-3 1.40 ± 0.05
*,# 
1.16 ± 0.03
* 
0.93± 0.04
*,# 
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properties, making these gels particularly desirable for tissue engineering applications. 
However, in the present study, the biological blank slate character of PEGDA also 
allowed observed cell binding to Scl2-F containing gels to be attributed to the presence 
of the Scl2-F protein alone. At the Scl2-F levels employed in the present study, the 
modulus and mesh structure of the PEG-Scl2 gel network can be expected to be 
dominated by PEGDA. To confirm this, the modulus of the prepared PEG-Scl2 
hydrogels was compared to that of pure 5 wt% PEG (3.4 kPa) hydrogels. Mechanical 
testing showed the compressive modulus of the PEG-Scl2 gels to be 139 ± 13 kPa, 
statistically indistinguishable from the 128 ± 11 kPa modulus of the pure PEG gel 
counterparts. The close agreement between these initial moduli indicates that the 
material properties of the PEG-Scl2 hydrogels are dominated by the PEGDA at the Scl2 
concentrations employed. Thus, these hybrid hydrogels appear to retain many of the 
beneficial properties of pure PEG gels, such as the ability to broadly tune modulus by 
varying the PEGDA Mw and/or concentration [123].  
To confirm the continued ability of gel-associated Scl2-F proteins to mediate 
specific cell adhesion, C2C12, C2C12-α1 and C2C12-α2 were seeded onto various 
hydrogel surfaces (Figure 16). As anticipated, each cell type spread on collagen-F 
containing gels, although the extent of this spreading was in general significantly lower 
than on collagen-F. This observation is consistent with previous studies demonstrating a 
reduction in cell spreading with decreasing substrate stiffness, although increased steric 
hindrance resulting from collagen conjugation to the PEGDA network may also 
contribute [63]. Similarly, Scl2-2F promoted adhesion of C2C12-α1 and C2C12-α2. Scl2-
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3F gels, however, were unable to support C2C12-α2 adhesion, as can be seen by 
comparison with Scl2-1F gels and PEG negative controls (Figure 16). These 
observations confirm that functionalized Scl2 proteins can be incorporated into 3D 
matrices to generate cell selective, bioactive hydrogels. This result has significant 
implications for the tissue engineering field, where controlled attachment is needed to 
provide a bioactive graft interface in order to have a better control of scaffolds and 
investigate cell fate decisions. 
 
3.5. CONCLUSION 
 
In the current study, the collagen-mimetic proteins Scl2-1, Scl2-2, and Scl2-3 
were functionalized with photocrosslinking sites to enable incorporation into a three 
dimensional hydrogel matrix. Bioactive hydrogels were then fabricated by combining 
the functionalized Scl2s with PEGDA and photocrosslinking via exposure to UV light. 
Characterization studies confirmed that the functionalization of the Scl2 proteins did not 
disrupt triple helix conformation, integrin binding, or cell adhesion. Initial cell studies 
also confirmed specific hMSC adhesion to Scl2-2 and Scl2-3 proteins and appropriate 
activation of different MAP kinase pathways due to selective integrin binding. 
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Figure 16. PEG-Scl2 hydrogels were fabricated by combining 5 wt.% PEGDA (3.4 kDa) with 
photoinitiator (Irgacure 2959), 6 mg protein ml
-1
 of Scl2-1F, Scl2-2F, Scl2-3F or functionalized type I 
collagen. PEG hydrogels served as a negative control. Cells were seeded at a density of 10,000 cell cm
-2
 
and allowed to spread for 3 h. Attached cells were fixed with 4% paraformaldehyde, stained with 
rhodamine phalloidin and SybrGreen, and imaged by fluorescence microscopy. Large circles in the Scl2-1 
images are a result of floating, non-adherent cells outside of the focal plane. The scale bar applies to all 
images and equals 100 µm. 
 
 
 64 
 
CHAPTER IV 
EVALUATION OF THE EFFECT OF COLLAGEN-MIMETIC PROTEINS IN 
HUMAN MESENCHYMAL STEM CELL OSTEOGENESIS 
 
4.1. OVERVIEW 
 
The results from the study of the novel collagen-mimetic proteins for the 
fabrication of hybrid polymeric scaffolds indicated that collagen-mimetic proteins Scl2-
1, Scl2-2, and Scl2-3 can be functionalized with photocrosslinking sites and therefore, 
incorporated into hydrogel matrices. In addition, human mesenchymal stem cell (hMSC) 
adhesion studies confirmed that these cells are able to bind specifically to Scl2-2 and 
Scl2-3 proteins and that appropriate MAP kinase signaling is activated due to the 
selective integrin binding motifs. The current work examines the influence of integrin α1 
and α2 binding on hMSC osteogenesis toward the goal of deconvoluting the impact of 
integrin-based interactions on associated cell behavior. 
Scl2-1, Scl2-2 and Scl2-3 proteins were conjugated into poly(ethylene glycol) 
diacrylate (PEGDA) hydrogels and their effects on encapsulated human MSCs were 
evaluated. Specifically, following 2 weeks of culture, various osteogenic markers were 
examined in order to assess the impact of integrin α1 and α2 on the observed responses. 
hMSCs encapsulated in PEG-Scl2-3 gels showed increased expression of osterix and 
osteopontin relative to PEG-Scl2-2 gels. However, calcium deposition, considered by 
many to be the ultimate indicator of osteogenesis, was increased in PEG-Scl2-2 gels 
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relative to PEG-Scl2-3. Although these results appear to be contradictory, they may also 
reflect distinct transitional phenotypes en route to hMSCs becoming osteoblasts.  
 
4.2. INTRODUCTION 
 
Recent advances in adult mesenchymal stem cell (MSC) research have shown 
these cells to be a promising patient-derived cell source that may address many of the 
limitations of differentiated adult cells [3, 4]. Not only are they capable of extensive 
proliferation, but they also have the capacity to differentiate into a range of cell types [3, 
5]. A number of 2D studies have demonstrated MSC osteogenic differentiation to be 
tightly regulated by cellular interactions with the surrounding extracellular matrix 
(ECM) [21, 18, 26-34]. However, comparatively, little is known regarding the effects of 
various ECM components in regulating MSC osteogenesis in 3D scaffold environments 
[17, 35-36]. This is significant since recent studies suggest that effects observed in 2D 
may not be indicative of the effects of the same scaffold variables in more biomimetic 
3D culture systems. 
Over the past ~20 years, the multiple facets of matrix-mediated signaling, beyond 
the identity and concentration of biochemical cues, have become increasingly 
appreciated [124]. For example, integrins, cell surface receptors which interact with a 
range of ECM proteins, were first recognized for their function in translating biopolymer 
identity into a cell response [49]. However, they also act as mechanical transducers by 
serving as organizing centers for focal adhesion complexes and associated cytoskeletal 
 66 
 
networks [124, 125]. The profound effects of integrin-mediated translation of matrix 
elastic modulus on MSC lineage commitment has been elegantly demonstrated in 2D 
using collagen I-coated polyacrylamide gels [126]. 
Despite these advances, our understanding of cell behavior is not yet sufficient to 
enable the rational selection of stimuli to elicit desired cell responses [7, 8]. Towards this 
goal, we propose to investigate the impact of specific integrin binding sequences 
(integrin α1 and α2) on MSC osteogenesis in 3D contexts using a collagen-mimetic 
protein, Scl2, which was initially discovered by Dr. Lukomski of West Virginia 
University and Dr. Höök of Texas A&M Health Science Center [87, 127]. The “parent” 
Scl2 protein maintains the native triple helical structure of native collagen but contains 
no known cell signaling sequences [85,105]. Thus, Scl2 provides a “blank-slate” into 
which desired collagen-based, cell adhesion sequences can be programmed by site-
directed mutagenesis while maintaining the triple helical context natively associated 
with these motifs.  
Scl2 proteins were conjugated into poly(ethylene glycol) diacrylate (PEGDA) 
hydrogel networks. PEGDA hydrogels were selected as the base scaffold due to the 
broad tunability of their mechanical properties and their previous use in bone 
regeneration applications [45-48]. In addition, PEGDA hydrogels were selected to be 
used as the material platform since they function as biological “blank slates” in that they 
intrinsically resist protein adsorption and cell adhesion [13, 128, 129]. This characteristic 
will permit us to focus on the bioactive signals introduced into the hydrogels by the Scl2 
proteins. Furthermore, pure PEGDA gels are highly biocompatible and degrade over a 
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period of 1-2 years by the hydrolysis of the ester bonds [130, 131], which will allow to 
keep the material degradation rate approximately constant within the time frame of our 
experiments. 
In the present study, human MSCs were encapsulated within PEGDA hydrogels 
containing defined amounts of Scl2-1, Scl2-2 or Scl2-3 proteins. Following 14 days of 
culture, the levels of various markers of osteogenic differentiation markers (Runx2, 
osteopontin and osterix) were monitored and the deposition of ECM components 
associated with mature bone (calcium phosphate) was also assessed. 
 
4.3. MATERIALS AND METHODS 
 
4.3.1. Polymer and protein synthesis and characterization  
 
4.3.1.1. PEG-diacrylate synthesis 
PEGDA was prepared as previously described [50] by combining 0.1 mmol ml
-1
 
dry PEG (3.4 kDa, Fluka), 0.4 mmol ml
-1
 acryloyl chloride and 0.2 mmol ml
-1
 
triethylamine in anhydrous dichloromethane and stirring under argon overnight. The 
resulting solution was washed with 2 M K2CO3 and separated into aqueous and 
dichloromethane phases to remove HCl. The organic phase was subsequently dried with 
anhydrous MgSO4, and PEGDA was precipitated in diethyl ether, filtered and dried 
under vacuum. Acrylation of the PEG end hydroxyl groups was characterized by proton 
nuclear magnetic resonance (
1
H-NMR) to be ~96%. 
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4.3.1.2. Purification, expression and mutagenesis of Scl2 proteins 
Desired bioactivity can be programmed into specific regions of the triple helix 
via site-directed mutagenesis of the gene encoding for Scl2. In conjunction with Dr. 
Russell of the Höök lab (Institute of Biosciences and Technology, Texas A&M 
University, System Health Science Center), two “daughter” Scl2s, Scl2-2 and Scl2-3, 
were engineered, which incorporate α1β1 and or α2β1 integrin-binding motifs based on 
the collagen sequences GF/LOGER [20, 107] (O; hydroxyproline). Specifically, Scl2-2 
and Scl2-3 were generated by encoding for sequences GFPGER and GFPGEN, 
respectively, using site-directed mutagenesis of the plasmid encoding for Scl2-1. 
Recombinant proteins were expressed using standard recombinant protein procedures in 
E. coli BL21 (Novagen) and purified by affinity chromatography on a HisTrap HP 
column (GE Healthcare). Protein purity was determined by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) followed by Coomassie blue staining. 
Furthermore, Scl2 proteins were dialyzed against water and stored at -20°C followed by 
lyophilization. 
 
4.3.1.3. Synthesis of acrylate-derivatized Scl2 protein 
In order to conjugate the different Scl2 proteins within the PEGDA-based 
hydrogel networks, Scl2-1, Scl2-2 and Scl2-3 were reacted with acryloyl-PEG-N-
hydroxysuccinimide (ACRL-PEG-NHS, 3.4 kDa, Nektar, San Carlos, CA) at a 1:2 
molar ratio for 2 h in 50mM sodium bicarbonate buffer, pH 8.5 [50]. The resulting 
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acrylate-derivatized products were purified by dialysis against double deionized water 
using a 10 kDa membrane, lyophilized and stored at -20 °C until use.  
 
4.3.2. Cell culture and encapsulation 
 
4.3.2.1. Cell culture 
Cryopreserved hMSCs (Lonza) at passage 3 were thawed and expanded in 
monolayer culture per Lonza protocols. Prior to encapsulation, cells were maintained at 
37 ºC and 5% CO2 in MesenPRO RSTM Media (Gibco) supplemented with 2% 
MesenPRO RSTM growth supplement (Gibco). Cells at passage 5–6 were harvested and 
allocated for hydrogel encapsulation. 
 
4.3.2.2. Hydrogel encapsulation 
Hydrogels were fabricated by preparing: 1.) a 20 wt% 3.4kDa PEGDA solution 
in HEPES-buffered saline (HBS) and 2.) individual solutions of 10 mg mL
-1
 acrylate-
derivatized Scl2-1, Scl2-2 or Scl2-3 in double deionized water. A 300 mg ml
-1
 solution 
of UV photoinitiator 2,2-dimethoxy-2-phenyl-acetophenone in N-vinylpyrrolidone was 
added at 2 (v/v)% to the PEGDA mixture. The PEGDA and protein solutions were then 
separately sterilized by filtration, after which each protein solution was mixed with an 
equal volume of the 20 wt% PEGDA solution. Harvested hMSCs were resuspended in 
the resulting precursor solutions at 1.5x10
6
 cells mL
-1
. The cell suspensions were then 
pipetted into molds composed of two glass plates separated by 0.75 mm polycarbonate 
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spacers and polymerized by 2 min exposure to longwave UV light (Spectroline, ~6 mW 
cm
-2
, 365 nm). The resulting hydrogel was removed from each mold, rinsed with 
phosphate buffered saline (PBS, pH 7.4; Sigma) and immersed in DMEM supplemented 
with 10% MSC-qualified FBS and 1% PSA (PSA. 10,000 U mL
-1
 penicillin, 10,000 mg 
L
-1
 streptomycin, and 25 mg L
-1
 amphotericin; Gibco) at 37 ºC and 5% CO2. After 3 h to 
allow for equilibrium swelling, the hydrogel slabs were separated into uniform gels discs 
using an 8 mm biopsy punch (Miltex). Each disc was transferred to a distinct 12-well 
culture insert fitted with a porous membrane (BD Biosciences). Following transfer of the 
gel discs, 1.5 mL of DMEM supplemented with 10% MSC-qualified FBS and 1% PSA 
and osteogenic supplements (0.1 μM dexamethasone, 50 μM ascorbate-2-phosphate and 
10 mM β-glycerophosphate [132]) was added to each well. After 24 h of culture at 37 ºC 
and 5% CO2, the media surrounding each sample was fully exchanged, after which full 
media changes were performed every two days during two weeks. 
 
4.3.3. Day 0 hydrogel characterization 
 
4.3.3.1. Average mesh size 
PEGDA hydrogel mesh structure cannot be visualized using standard techniques 
such as scanning electron microscopy. In the present study, average hydrogel mesh size 
was therefore characterized via a series of dextran diffusion experiments based on an 
adaptation of the methodology of Watkins and Anseth [52]. In brief, samples were 
collected from the freshly prepared PEG-Scl2 hydrogels and allowed to swell overnight 
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at 37 °C in PBS containing 0.05% azide (PBS-azide). Eight-millimeter-diameter discs 
were then harvested from each gel formulation, and solutions containing 0.05 mg ml
-1
 
fluorescently labeled dextran (10 kDa, Invitrogen) in PBS-azide were added at 1 ml per 
hydrogel disc. Dextran solutions were allowed to diffuse into the hydrogels for 24 h at 
37 °C. Each gel disc was then gently blotted and transferred to 1 ml fresh PBS-azide. 
Dextran that had penetrated into the hydrogels was then permitted to diffuse out into the 
surrounding solution at 37 °C. After 24 h, the fluorescence of the PBS-azide solution 
surrounding each disc was measured at ex/em 488/532. Dextran standard curves were 
used to convert each fluorescence signal to a concentration. For each hydrogel, the 
measured dextran concentration was divided by gel weight [53]. The resulting value 
served as a quantitative indicator of hydrogel permissivity. 
 
4.3.3.2. Hydrogel mechanical assessment  
Mechanical analyses were conducted using a modification of the circumferential 
property testing technique validated in Johnson et al. [133] and Hiles et al. [134]. In 
brief, the dimensions of ring segments 2–4 cm in width were measured using digital 
calipers. These measures served as dimension inputs for subsequent stress and strain 
calculations and as swelling indicators. Each ring was mounted onto an Instron 3342 by 
threading opposing stainless steel hooks through the segment lumen. The hooks were 
then uniaxially separated at a rate of 6 mm min
-1
 until construct failure. As hook 
separation increased, the mounted ring was drawn into an increasingly oblong oval 
conformation. Johnson et al. confirmed that the force applied by the hooks to this oblong 
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oval could be approximated as being equally distributed between two parallel rectangles, 
each with sides equal to the width and wall thickness, hv, of the ring. The gauge length, 
lg, was taken to be the inner diameter, Dv, of the unstretched ring plus hv, and the elastic 
modulus, E, of each sample was defined as the slope of the resulting stress–strain curve 
at a reference stress of 20 kPa [135]. Samples remained immersed in PBS until 
immediately prior to mechanical analyses, and testing was completed rapidly to avoid 
sample dehydration. 
 
4.3.3.3. Cell density 
Samples (n = 4) were collected from each freshly prepared hydrogel formulation 
following 24 h immersion in culture media. Hydrogel samples were digested for 72 h at 
37 °C in 1 ml of 0.12 M NaOH per 0.2 g hydrogel wet weight [54, 55]. Aliquots of the 
hydrolyzed samples were neutralized, and their DNA content determined using the 
Invitrogen PicoGreen assay [56]. DNA measures were translated to cell number using a 
conversion factor of 6.6 pg DNA per cell [57]. Calf thymus DNA (Sigma) subjected to 
the same association with PEGDA and to the same digestion conditions as the samples 
served as a standard. 
 
4.3.4. Endpoint analyses 
 
At day 14 of culture, samples were harvested from each hydrogel formulation for 
mechanical, mesh size, DNA, calcium deposition and protein analyses (western blots). 
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Samples harvested for mechanical (n = 4 per formulation), mesh size (n = 4 per 
formulation) and DNA (n = 4 per formulation) assessments were evaluated according to 
the same protocols as the day 0 specimens. Samples collected for calcium deposition and 
protein analyses (n = 6 per formulation) were homogenized in lysis buffer (100 mM 
Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM EDTA pH 8.0, 1% LiDS, 5 mM dithiothreitol 
(DTT)) and supernatant was isolated by centrifugation. A second extraction from the 
pellet was performed by freezing and thawing it three times, and the final solution was 
centrifuged one more time to isolate the supernatant, which was combined with the 
supernatant obtained from the homogenization. Protein levels were assessed via CBQCA 
protein quantitation kit (Molecular Probes). Isolated protein solutions were used for both 
calcium deposition measurements and western blot analyses. 
 
4.3.4.1. Total calcium deposition.  
To assess construct calcium levels, hydrogel discs (n = 6 per formulation) were 
homogenized in lysis buffer (100 mM Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM EDTA 
pH 8.0, 1% LiDS, 5 mM dithiothreitol (DTT)) as described previously. Total calcium 
was quantified using 10 μl aliquots of each sample homogenate via the Calcium 
Cresolphthalein Complexone (CPC) liquid color kit (Stanbio). 
 
4.3.4.2. Western blot analyses 
Equal amounts of protein (20 µg per lane) were loaded into different wells of a 
10% polyacrylamide gel and proteins were separated by electrophoresis. Before loading 
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the samples onto the gel, protein solutions were concentrated using 3,000 MWCO 
Amicon filter units (Millipore), and proteins were denatured by addition of β-
mercaptoethanol solution and heating at 100 °C for 10 minutes. After electrophoresis, 
proteins were transferred to a nitrocellulose membrane (Thermo Scientific). The blot 
was cut into two parts, and washed twice with double distilled water for 5 minutes each 
time at room temperature. Blots were then blocked with a 5% BSA solution (Fraction V, 
Fisher Scientific) in Tris-buffered saline containing 0.1% Tween-20 (TBST; 25 mM 
Tris-HCl, pH. 7.5, 137 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. 
Following blocking incubation, blots were briefly rinsed with TBST. Each blot was 
incubated with the appropriate primary antibody diluted in TBST solution containing 5% 
BSA overnight at 4 °C. After washing three times with TBST solution, primary antibody 
bound to each blot was detected using an appropriate HRP or AP conjugated secondary 
antibody (Jackson Immunoresearch) diluted in TBST solution containing 5% BSA for 1 
hour at room temperature. Blots were again washed three times with TBST solution, and 
signal was detected using a luminol reagent (SCBT) or an AP chemiluminescent solution 
(Novex). Imaging was performed using the molecular imager chemidoc XRS system 
(Biorad) and band intensity was quantified using Adobe Phothoshop. 
Detection of Runx2, osteopontin (OPN) and osterix (OSX) proteins were 
performed using Runx2 (M-70) (1:500, Santa Cruz Biotechnology, California, USA, sc-
10758), OPN (AKm2A1) (1:500, Santa Cruz Biotechnology, sc-21742) and OSX (M-
15)-R (1:500, Santa Cruz Biotechnology, sc-22538-R) antibodies, respectively. Runx2, 
OPN and OSX levels were normalized with respect to beta actin levels (Abcam).  
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4.3.5. Statistical analyses 
 
Data are reported as mean ± standard deviation. Comparison of sample means 
was performed by ANOVA followed by Tukey’s post hoc test (SPSS software), p < 
0.05. 
 
4.4. RESULTS AND DISCUSSION 
 
4.4.1. Hydrogel material properties and cell density 
 
A range of scaffold properties, including modulus, permeability and degradation 
rate, have been found to impact MSC lineage progression. Therefore, in order to 
attribute differences in hMSC behavior across hydrogel formulations, specifically to 
initial differences in gel protein composition, it was important that the remaining 
hydrogel material properties could be considered consistent across gels. Hydrogels 
formed from pure PEGDA degrade slowly (over a period of 1–2 years) and resist cell-
mediated gel contraction, ensuring consistent bulk gel properties over a broad time range 
[55, 56, 61-63]. In the present study, a 20:1 weight ratio of PEGDA to protein was 
therefore selected to ensure that the network properties of the resulting gels would be 
dominated by PEGDA. To confirm this, the modulus, mesh size, thickness and mass of 
the PEG–ECM hydrogels were characterized both at day 0 and at day 7. 
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As shown in Table 7, the initial elastic moduli of the PEG–Scl2-1, PEG–Scl2-2 
and PEG–Scl2-3 gels were similar at ~158 kPa. To assess degradation and cell-mediated 
contraction, hydrogel modulus and thickness were evaluated across time in culture. 
Comparison of initial and endpoint mechanical data indicated that, hydrogel modulus 
remained consistent across formulations (Table 7). Similarly, average mesh size was 
consistent across hydrogels at both day 0 and day 7 (Table 7). The initial and endpoint 
thickness data for 8 mm gel discs indicated a negligible alteration in gel volume with 
time. In addition, net cell proliferation and loss were examined for each PEG–Scl2 
hydrogel over the 14 day culture period. The cell density in each PEG–Scl2 hydrogel 
following 14 days of culture did not significantly changed from the initial seeding 
density (Table 8). Combined, the above data indicate that: (1) each hydrogel formulation 
maintained a consistent modulus throughout the study and (2) differences in cell 
responses among formulations can be attributed to differences in the initial proteins 
tethered to the gel network, their interactions with other molecules and subsequent neo-
matrix deposition. 
 
Table 7. Comparison of the average modulus and mesh size of 8 mm discs of each PEG–
Scl2 hydrogel formulation with time in culture.
a
 
 
 
 
 
 
 
 
 
 
a
 Property results represent an average of n = 4 samples for each PEG-Scl2 formulation 
b
 Mesh size data was normalized using Scl2-1 data 
 
Gel type 
Modulus (kPa) Mesh size (µg dextran/g-gel)
b 
Day 0 Day 14 Day 0 Day 14 
PEG-Scl2-1 157.50 ± 2.12 155.50± 9.19 1.00 ± 0.01 1.00± 0.03
 
PEG-Scl2-2 158.50 ± 7.78 167.70± 2.31 0.98 ± 0.01 1.02± 0.03
 
PEG-Scl2-3 160.50 ± 0.00 163.50± 4.95 0.98 ± 0.01 1.01± 0.02
 
 77 
 
Table 8. Comparison of the average thickness, mass, and cell density in discs of each 
PEG–Scl2 hydrogel formulation with time in culture.a 
 
a 
Results represent an average of n = 4 samples for each PEG–Scl2 formulation. 
 
 
4.4.2. Cell differentiation 
 
The effect of collagen-mimetic proteins on the osteogenic differentiation of 
hMSCs was evaluated. Human MSCs in PEG-Scl2 hydrogels were cultured in 
osteogenic medium containing dexamethasone, ascorbic acid and β-glycerophosphate for 
2 weeks. The extent of calcium deposition on the different hydrogel scaffolds was 
examined via Calcium CPC liquid color kit after this period of time. As shown in Figure 
17, quantitative CPC assays revealed a significantly increase in calcium deposits in the 
PEG-Scl2-2 gels relative to the PEG-Scl2-3 gels (p < 0.021).  
In addition to calcium deposition analyses, following 14 days of culture, 
osteogenic differentiation markers were examined by western blot assays (Table 9). As 
shown in Figure 18, day 14 levels of various osteogenic markers indicated significant 
differences among hydrogel formulations. Specifically, although Runx2 levels did not 
vary between the different hydrogel formulations, cells in PEG-Scl2-3 gels expressed 
significantly higher levels of osterix than in PEG-Scl2-1 and PEG-Scl2-2 formulations 
Gel type 
Thickness (mm) Mass of 8mm discs (mg) Cell density (x10
6
) 
Day 0 Day 14 Day 0 Day 14 Day 0 Day 14 
PEG-Scl2-1 0.76 ± 0.01 0.78± 0.01 23.20 ± 0.14 22.90± 0.15 1.43± 0.04 1.47± 0.12
 
PEG-Scl2-2 0.76 ± 0.01 0.78± 0.01 23.20 ± 0.07 23.00± 0.12 1.33± 0.05 1.45± 0.08
 
PEG-Scl2-3 0.76 ± 0.01 0.77± 0.01 23.70 ± 0.14 22.40± 0.55 1.34± 0.07 1.33± 0.16 
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(p < 0.001 and p = 0.027, respectively). Also, osterix expression in PEG-Scl2-2 gels was 
significantly higher relative to PEG-Scl2-1 gels (p = 0.002). Regarding osteopontin 
expression, both PEG-Scl2-2 and PEG-Scl2-3 gels showed apparent higher levels than 
Scl2-1 gels; however, statistically differences were only found between PEG-Scl2-1 and 
PEG-Scl2-3 gels (p = 0.027).  
 
 
Figure 17. Calcium measures per hydrogel formulation (n = 6 per formulation). Hydrogel discs were 
homogenized and total calcium was quantified using 10 μl aliquots of each sample homogenate via the 
CPC liquid color kit. 
*
indicates a significant difference, p < 0.05. 
 
 
Table 9. Osteogenic markers that were investigated in the present work. 
 
 
 
 
 
 
 
 
Marker Description 
Runx2 Early osteogenic transcription factor 
Osterix Mid-term osteogenic transcription factor 
Osteopontin Bone ECM protein 
Calcium deposition Late-term bone marker 
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Figure 18. Expression of osteogenic markers osterix, osteopontin and Runx2 by western blot. For 
western blot assays, six samples per formulation (day 14) were analyzed. For the purpose of comparison, 
western blot measures for each protein have been normalized to the corresponding measure for PEG-Scl2-
1 gels.  
*
indicates a significant difference, p < 0.05. 
 
 
Data obtained for osterix and osteopontin expression indicated that PEG-Scl2-3 
gels enhanced the osteogenic response of encapsulated hMSCs. Specifically, osterix and 
osteopontin levels in day 14 PEG-Scl2-3 gels were ~ 1.4- and 1.2-fold greater, 
respectively, than PEG-Scl2-2 gels. However, data collected for calcium deposition 
suggested that PEG-Scl2-2 gels enhanced osteogenic response of hMSCs since there was 
an increase in mineralization in PEG-Scl2-2 gels relative to PEG-Scl2-3 gels (~ 1.3- fold 
greater). The present results are consistent with previous studies in such as literature also 
presents conflicting reports regarding the osteoinductivity of integrin α1 and α2 units. 
Specifically, while several studies have suggested that both integrin α1 and α2 are 
involved in osteogenesis [136, 137], other studies have reported no involvement of 
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integrin α1 [138, 139]. Clover et al. indicated that human bone cells primarily express 
integrin α1 (osteoblasts) and integrin α2 (osteoclasts) motifs. However, they found that 
expression of α2 was independent on cell density, while expression α1 was much greater 
in confluent cultures [136]. Similarly, Jikko et al. found that by function-perturbing α1 
and or α2 integrin subunits in murine 2T3 osteoblastic cells, not only the expression of 
early osteoblast markers was decreased more than 90% but also mineralization of these 
cells was blocked. In addition, they found that blocking by separate α1 or α2 integrin 
subunits produced partial effects by comparing the results when both subunits were 
perturbed combined [137]. In contrary to these studies, Foster et al. revealed that integrin 
α2 plays a role in increased intracellular calcium upon cell adhesion to extracellular 
matrix in hMSCs differentiation toward osteoblasts [139]. Likewise, Popov et al. showed 
that integrin α2 but not α1 was significantly upregulated on osteogenic stimulation of 
human MSCs [138].  
Several reports have also studied the independent osteoinductive role of either 
integrin α1 or integrin α2. In particular, Gronthos et al. found that incubating 
preosteoblasts with a function blocking antibody against integrin α1 inhibited matrix 
mineralization [140]. In addition, Salaszynk et al. found that collagen I-coated surfaces 
stimulated human MSC matrix mineralization, and that cell interactions with these 
surfaces were initially mediated primarily by α1 subunits (>90% of adhesive 
interactions) [26]. As with integrin α1, integrin α2 has also been associated with 
osteogenesis. Specifically, Mizuno et al. indicated that expression of osteoblastic 
phenotypes was suppressed by blocking the binding of integrin α2 to collagen. Indeed, 
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they found a decrease of ~35% and ~50% in alkaline phosphatase and osteocalcin 
expression, respectively. Similarly, Reyes et al. demonstrated that α2 integrin triggers the 
activation of multiple osteoblast-specific genes such as alkaline phosphatase, osteocalcin 
and bone sialoprotein as well as the induction of matrix mineralization in MC3T3-E1 
murine immature osteoblast-like cells [141]. 
Although these results appear to be contradictory, they may also reflect distinct 
transitional phenotypes en route to hMSCs becoming osteoblasts [142]. Further work 
studying the influence of the initial cell signaling in osteogenesis will be conducted in 
order to try to better understand the influence of integrin α1 and α2 binding motifs in 
osteogenesis of hMSCs. 
 
4.5. CONCLUSION 
 
In the current study, toward the goal of deconvoluting the impact of integrin-based 
interactions on associated cell behavior, the influence of select integrin binding 
sequences on hMSC osteogenesis was investigated. Scl2-1, Scl2-2 and Scl2-3 proteins 
were conjugated into poly(ethylene glycol) diacrylate (PEGDA) hydrogels and their 
effects on encapsulated human MSCs were evaluated. Contradictory results were found 
in such as both PEG-Scl2-2 and PEG-Scl2-3 were osteoinductive. Nevertheless, this may 
reflect that by transmitting signals from the environment to the interior of the cell, the 
type of integrin expressed can influence osteogenic phenotypic behavior of hMSC. 
Finally, to gain insight into the origins of the found osteogenic responses, future work 
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that involves the study of p38 and FAK pathways in osteogenesis of hMSC will be 
necessary in order to establish its potential causative relationship with Scl2 proteins. 
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CHAPTER V 
PRELIMINARY STUDY OF THE INFLUENCE OF THE P38 MAP KINASE 
SIGNALING IN HUMAN MESENCHYMAL STEM CELL OSTEOGENESIS USING 
A COLLAGEN-MIMETIC PROTEIN IN THREE DIMENSIONAL (3D) CONTEXTS 
 
5.1. OVERVIEW 
 
The results from the study of the effect of collagen-mimetic proteins in human 
mesenchymal stem cell osteogenesis were conflicting since both Scl2-2 and Scl2-3 were 
osteoinductive, but in different ways. To better understand the influence of the initial 
activation of cell signaling underlying these results, a series of experiments was 
conducted in which activation of p38 was inhibited. The p38 MAP kinase was selected 
for inhibition due to results from the study of the novel collagen-mimetic proteins that 
revealed that FAK and p38α MAP kinases were more activated when hMSCs were 
exposed to Scl2-2 protein relative to Scl2-3.  
The presence of multiple MAP kinase signal transduction pathways and the 
extent to which each is activated during differentiation may reflect the integration of 
multiple signals and the balance among ERK, p38, and JNK MAP kinases. The current 
work examines the influence of p38α MAP kinase on osteogenic differentiation of 
hMSCs. However, chemical inhibitors could possibly affect more than one signaling 
pathway because of their reciprocal influence on cellular targets; therefore, different 
pathways will be analyzed as well as the osteogenic response of the cells.  
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Scl2-2 protein was conjugated into poly(ethylene glycol) diacrylate (PEGDA) 
hydrogels and p38 pathway was inhibited in order to evaluate its effect on encapsulated 
human MSC behavior. Specifically, MAP kinase shunts were examined at day 0 of the 
encapsulation in order to confirm p38 inhibition in response to the p38 inhibitor and to 
assess influence on the other MAP kinase pathways. In addition, following 2 weeks of 
culture, various osteogenic markers were examined in order to assess the impact of the 
p38 MAP kinase inhibition on the observed responses. The inhibition of the p38 
pathway reduced the expression of osteogenic markers (Runx2, OPN and osterix), which 
suggest that this MAP kinase protein may regulate osteogenesis in hMSCs. Nevertheless, 
FAK activation was also reduced by inhibiting the p38 pathway. These results confirm 
that MAP kinase pathways play an important role in osteogenesis and that the extent to 
which each is activated during differentiation may reflect the integration of multiple 
signals. 
 
5.2. INTRODUCTION 
 
Several reports have shown opposing roles of the MAP kinase signaling 
pathways in osteogenic differentiation, which indicates that the role of the MAP kinase 
signaling pathway in osteoblastic differentiation is currently unclear. In fact, our results 
suggest that p38 and/or FAK pathways might be involved in osteogenesis of hMSCs. 
Also, several studies have shown that both FAK and p38 influence osteogenesis [18, 25, 
31, 143-148]. Particularly, Salasznyka et al. indicated that by inhibiting FAK activation 
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by ~40%, osterix and osteogenic genes associated with osteogenic differentiation were 
reduced, results that suggest that FAK signaling plays an important role in regulating 
osteogenesis of hMSC [25]. In addition, Jaiswal et al. showed that p38 influences 
osteogenesis in the late stage by increasing alkaline phosphatase activity, and initiation 
of mineral deposition [145]. In the same way, Ortuno et al. revealed that BMP-2-
activated p38 which enhances the transcriptional activity of osterix [146].  
To establish the primary causative signaling mechanisms regulating osteogenic 
MSC differentiation in response to α1 and α2 integrin-mediated stimuli, human MSCs 
were encapsulated within PEGDA hydrogels containing defined amount of Scl2-2 
protein and the p38 pathway was inhibited. Following encapsulation, MAP kinase shunts 
were examined in order to confirm p38 inhibition and to assess its influence in the other 
MAP kinases. Also, after 14 days of culture, the levels of various osteogenic markers 
(Runx2, osteopontin and osterix) were monitored in order to assess the impact of the p38 
MAP kinase on the observed responses. Understanding the dominant signaling 
underlying particular cell behavior will allow biomaterials to be specifically designed to 
modulate these signaling cascades. 
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5.3. MATERIAL AND METHODS 
 
5.3.1. Polymer and protein synthesis and characterization  
 
5.3.1.1. PEG-diacrylate synthesis 
PEGDA was prepared as previously described [50] by combining 0.1 mmol ml
-1
 
dry PEG (3.4 kDa, Fluka), 0.4 mmol ml
-1
 acryloyl chloride and 0.2 mmol ml
-1
 
triethylamine in anhydrous dichloromethane and stirring under argon overnight. The 
resulting solution was washed with 2 M K2CO3 and separated into aqueous and 
dichloromethane phases to remove HCl. The organic phase was subsequently dried with 
anhydrous MgSO4, and PEGDA was precipitated in diethyl ether, filtered and dried 
under vacuum. Acrylation of the PEG end hydroxyl groups was characterized by proton 
nuclear magnetic resonance (
1
H-NMR) to be ~96%. 
 
5.3.1.2. Purification, expression and mutagenesis of Scl2 proteins 
Desired bioactivity can be programmed into specific regions of the triple helix 
via site-directed mutagenesis of the gene encoding for Scl2. In conjunction with Dr. 
Russell of the Höök lab (Institute of Biosciences and Technology, Texas A&M 
University, System Health Science Center), two “daughter” Scl2s, Scl2-2 and Scl2-3, 
were engineered, which incorporate α1β1 and or α2β1 integrin-binding motifs based on 
the collagen sequences GF/LOGER [20, 107](O; hydroxyproline). Specifically, Scl2-2 
was generated by encoding for sequences GFPGER using site-directed mutagenesis of 
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the plasmid encoding for Scl2-1. Recombinant protein Scl2-2 was expressed using 
standard recombinant protein procedures in E. coli BL21 (Novagen) and purified by 
affinity chromatography on a StrepTrap HP column (GE Healthcare). Protein purity was 
determined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) 
followed by Coomassie blue staining. Furthermore, Scl2 protein was dialyzed against 
water and stored at -20°C followed by lyophilization. 
 
5.3.1.3. Synthesis of acrylate-derivatized Scl2 protein 
In order to conjugate the different Scl2 proteins within the PEGDA-based 
hydrogel networks, Scl2-2 was reacted with acryloyl-PEG-N-hydroxysuccinimide 
(ACRL-PEG-NHS, 3.4 kDa, Nektar, San Carlos, CA) at a 1:2 molar ratio for 2 h in 
50mM sodium bicarbonate buffer, pH 8.5 [50]. The resulting acrylate-derivatized 
products were purified by dialysis against double deionized water using a 10 kDa 
membrane, lyophilized and stored at -20 °C until use.  
 
5.3.2. Cell culture and encapsulation 
 
5.3.2.1. Cell culture 
Cryopreserved hMSCs (Lonza) at passage 3 were thawed and expanded in 
monolayer culture per Lonza protocols. Prior to encapsulation, cells were maintained at 
37 ºC and 5% CO2 in MesenPRO RSTM Media (Gibco) supplemented with 2% 
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MesenPRO RSTM growth supplement (Gibco). Cells at passage 5–6 were harvested and 
allocated for hydrogel encapsulation. 
 
5.3.2.2. Hydrogel encapsulation 
Hydrogels were fabricated by preparing: 1.) a 20 wt% 3.4kDa PEGDA solution 
in HEPES-buffered saline (HBS) and 2.) separate solutions of 10 mg mL
-1
 acrylate-
derivatized Scl2-2 in double deionized water. A 300 mg ml
-1
 solution of UV 
photoinitiator 2,2-dimethoxy-2-phenyl-acetophenone in N-vinylpyrrolidone was added 
at 2 (v/v)% to the PEGDA mixture. The PEGDA and protein solutions were then 
separately sterilized by filtration, after which each protein solution was mixed with an 
equal volume of the 20 wt% PEGDA solution. Harvested hMSCs were resuspended in 
the resulting precursor solutions at 1.5x10
6
 cells ml
-1
. The cell suspensions were then 
pipetted into molds composed of two glass plates separated by 0.75 mm polycarbonate 
spacers and polymerized by 2 min exposure to longwave UV light (Spectroline, ~6 mW 
cm
-2
, 365 nm). The resulting hydrogel was removed from each mold, rinsed with 
phosphate buffered saline (PBS, pH 7.4; Sigma) and immersed in DMEM supplemented 
with 10% MSC-qualified FBS and 1% PSA (PSA. 10,000 U mL
-1
 penicillin, 10,000 mg 
L
-1
 streptomycin, and 25 mg L
-1
 amphotericin; Gibco) at 37 ºC and 5% CO2. After 1 h to 
allow for equilibrium swelling, cells were exposed to p38 inhibitor (SB203580,Cell 
signaling) at 10 μM. Inhibitor was dissolved in DMSO, and therefore the control gel 
received equivalent volumes of vehicle (DMSO). The DMSO concentration did not 
exceed 0.1% of the medium volume. After 6 h of culture at 37 ºC and 5% CO2, the 
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hydrogel slabs were separated into uniform gels discs using an 8 mm biopsy punch 
(Miltex). Each disc was transferred to a distinct 12-well culture insert fitted with porous 
membrane (BD Biosciences). Following transfer of the gel discs, 1.5 mL of DMEM 
supplemented with 10% MSC-qualified FBS and 1% PSA and osteogenic supplements 
(0.1 μM dexamethasone, 50 μM ascorbate-2-phosphate and 10 mM β-glycerophosphate 
[132]) with inhibitor supplementation was added to each well. After 24 h of culture at 37 
ºC and 5% CO2, the media surrounding each sample was fully exchanged, after which 
full media changes were performed every two days during two weeks. 
 
5.3.3. Day 0 hydrogel characterization 
 
5.3.3.1. Average mesh size 
PEGDA hydrogel mesh structure cannot be visualized using standard techniques 
such as scanning electron microscopy. In the present study, average hydrogel mesh size 
was therefore characterized via a series of dextran diffusion experiments based on an 
adaptation of the methodology of Watkins and Anseth [52]. In brief, samples were 
collected from the freshly prepared PEG-Scl2 hydrogels and allowed to swell overnight 
at 37 °C in PBS containing 0.05% azide (PBS-azide). Eight-millimeter-diameter discs 
were then harvested from each gel formulation, and solutions containing 0.05 mg ml
-1
 
fluorescently labeled dextran (10 kDa, Invitrogen) in PBS-azide were added at 1 ml per 
hydrogel disc. Dextran solutions were allowed to diffuse into the hydrogels for 24 h at 
37 °C. Each gel disc was then gently blotted and transferred to 1 ml fresh PBS-azide. 
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Dextran that had penetrated into the hydrogels was then permitted to diffuse out into the 
surrounding solution at 37 °C. After 24 h, the fluorescence of the PBS-azide solution 
surrounding each disc was measured at ex/em 488/532. Dextran standard curves were 
used to convert each fluorescence signal to a concentration. For each hydrogel, the 
measured dextran concentration was divided by gel weight [53]. The resulting value 
served as a quantitative indicator of hydrogel permissivity. 
 
5.3.3.2. Hydrogel mechanical assessment  
Mechanical analyses were conducted using a modification of the circumferential 
property testing technique validated in Johnson et al. [133] and Hiles et al. [134]. In 
brief, the dimensions of ring segments 2–4 cm in width were measured using digital 
calipers. These measures served as dimension inputs for subsequent stress and strain 
calculations and as swelling indicators. Each ring was mounted onto an Instron 3342 by 
threading opposing stainless steel hooks through the segment lumen. The hooks were 
then uniaxially separated at a rate of 6 mm min
-1
 until construct failure. As hook 
separation increased, the mounted ring was drawn into an increasingly oblong oval 
conformation. Johnson et al. confirmed that the force applied by the hooks to this oblong 
oval could be approximated as being equally distributed between two parallel rectangles, 
each with sides equal to the width and wall thickness, hv, of the ring. The gauge length, 
lg, was taken to be the inner diameter, Dv, of the unstretched ring plus hv, and the elastic 
modulus, E, of each sample was defined as the slope of the resulting stress–strain curve 
at a reference stress of 20 kPa [135]. Samples remained immersed in PBS until 
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immediately prior to mechanical analyses, and testing was completed rapidly to avoid 
sample dehydration. 
 
5.3.4. Initial and final analyses 
 
5.3.4.1. Protein extraction 
After 6 h of culture, samples were harvested from each hydrogel formulation in 
order to confirm p38 pathway inhibition by western blots. Samples were collected (n = 6 
per formulation) and homogenized in cell extraction buffer supplemented with protease 
and phosphate inhibitors (1% Triton, 0.1% SDS, 10 mM sodium fluoride, 1 mM sodium 
pyrophosphate, 2 mM sodium orthovanadate, 1x protease cocktail (Thermo Scientific) in 
PBS). Supernatant was isolated by centrifugation, and a second extraction from the 
pellet was performed by freezing and thawing it three times. The final solution was 
centrifuged one more time to isolate the supernatant, which was combined with the 
supernatant obtained from the homogenization. Protein levels of the resulting lysates 
were measured by the Bio-Rad DC protein assay. The activation of FAK, ERK1/2 and 
p38 MAP kinases was evaluated using western blot assay. 
Similarly, at day 14 of culture, samples were harvested from each hydrogel 
formulation for protein analyses (western blots). Samples collected for protein analyses 
(n = 6 per formulation) were homogenized in lysis buffer (100 mM Tris-HCl, pH 7.5, 
500 mM LiCl, 10 mM EDTA pH 8.0, 1% LiDS, 5 mM dithiothreitol (DTT)). Proteins 
were extracted according to the same protocol followed for the after 6 h specimens. 
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Protein levels were assessed via CBQCA protein quantitation kit (Molecular Probes). 
Isolated protein solutions were used for western blot analyses. 
 
5.3.4.2. Western blot analyses 
Equal amount of protein (10 or 20 µg per lane) were loaded into different wells 
of a 10% polyacrylamide gel and proteins were separated by electrophoresis. Before 
loading the samples onto the gel, protein solutions were concentrated using 3,000 
MWCO Amicon filter units (Millipore), and proteins were denatured by addition of β-
mercaptoethanol solution and heating at 100 °C for 10 minutes. After electrophoresis, 
proteins were transferred to a nitrocellulose membrane (Thermo Scientific). The blot 
was cut into two parts, and wash twice with double distilled water for 5 minutes each 
time at room temperature. Blots were then blocked with a 5% BSA solution (Fraction V, 
Fisher Scientific) in Tris-buffered saline containing 0.1% Tween-20 (TBST; 25 mM 
Tris-HCl, pH. 7.5, 137 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. 
After blocking incubation, blots were briefly rinsed once with TBST. Each blot was 
incubated with the appropriate primary antibody diluted in TBST solution containing 5% 
BSA overnight at 4 °C. Further details of antibodies can be found in Table 10. After 
washing three times with TBST solution, 5 minutes each time at room temperature, 
primary antibody bound to each blot was detected using an appropriated HRP or AP 
conjugated secondary antibody (Jackson Immunoresearch) diluted in TBST solution 
containing 5% BSA for 1 hour at room temperature. Blots were again washed three 
times with TBST solution, 5 minutes each time at room temperature, and signal was 
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detected using a luminol reagent (SCBT) or an AP chemiluminescent solution (Novex). 
Imaging was performed using the molecular imager chemidoc XRS system (Biorad) and 
band intensity was quantified using Adobe Phothoshop. 
 
5.3.5. Statistical analyses 
 
Data are reported as mean ± standard deviation. Comparison of sample means 
was performed by ANOVA followed by Tukey’s post hoc test (SPSS software), p < 
0.05. 
 
Table 10. Antibodies employed in western blot assays 
Antibody Clone Supplier Western blot 
FAK C-20 SCBT  
p-FAK Tyr 397 MP  
ERK1 K-23 SCBT  
p-ERK1/2 12E4 SCBT  
p38α F-9 SCBT  
p-p38 Thr 180/ Tyr 182 SCBT  
Runx2 M-70 SCBT  
Osteopontin AKm2A1 SCBT  
Osterix M-15-R SCBT  
Beta actin mAbcam 8226 Abcam  
 
†
Abbreviations: MP – Millipore; SCBT – Santa Cruz Biotechnology 
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5.4. RESULTS AND DISCUSSION 
 
The present study was designed to try to better understand the influence of p38 
MAP pathway in osteogenesis of hMSC in order to establish its potential causative 
relationship with Scl2 proteins. Toward this goal, hMSCs were encapsulated in PEG-
Scl2-2 hydrogel networks and p38 pathway was inhibited during 2 weeks of culture. 
After this time, osteogenic markers were evaluated using western blot assays.  
 
5.4.1. Hydrogel material properties  
 
A range of scaffold properties, including modulus, permeability and degradation 
rate, have been found to impact MSC lineage progression. Therefore, in order to 
attribute differences in hMSC behavior across hydrogel formulations, specifically to p38 
inhibition, it was important that the remaining hydrogel material properties could be 
considered consistent across formulations. Hydrogels formed from pure PEGDA 
degrade slowly (over a period of 1–2 years) and resist cell-mediated gel contraction, 
ensuring consistent bulk gel properties over a broad time range [55, 56, 61-63]. In the 
present study, a 20:1 weight ratio of PEGDA to protein was therefore selected to ensure 
that the network properties of the resulting gels would be dominated by PEGDA. To 
confirm this, the modulus, mesh size, thickness and mass of the PEG–ECM hydrogels 
were characterized after encapsulation. 
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As shown in Table 11, the initial elastic moduli of the PEG–Scl2-2 p38 (gel that 
was cultured with media supplemented with p38 inhibitor) and PEG–Scl2-2 DMSO 
(control gel) hydrogels were similar at ~158 kPa. Similarly, average mesh size was not 
significantly different across hydrogels (Table 11). In addition, the initial thickness data 
for 8 mm gel discs was also consistent among formulations. Combined, the above data 
indicate that: (1) each hydrogel formulation has similar mechanical properties and (2) 
differences in cell responses among formulations can be attributed to differences in cell 
culture conditions that were used for the hydrogels, their interactions with other 
molecules and subsequent neo-matrix deposition. 
 
Table 11. Comparison of the average modulus and mesh size of 8 mm discs of each 
PEG–Scl2 hydrogel formulation with time in culture.a 
 
a
 Property results represent an average of n = 4 samples for each PEG-Scl2 formulation 
 
 
5.4.2. Inhibition studies 
 
To study the influence of the p38 MAP kinase pathway in osteogenesis of 
hMSCs, a specific p38 inhibitor was used (SB203580). Human MSCs were encapsulated 
in PEG-Scl2-2 hydrogels, and cells were exposed to p38 inhibitor at 10 μM. Inhibitor 
was dissolved in DMSO, and therefore the control gel received equivalent volumes of 
Gel type Modulus (kPa) 
Mesh size (µg 
dextran/g-gel)
 
Thickness 
(mm) 
Mass of 8mm 
discs (mg) 
PEG-Scl2-2 p38  158.30± 4.04 0.021± 0.001 0.760 ± 0.002 22.20 ± 0.12 
PEG-Scl2-2 DMSO 158.00± 2.83 0.020± 0.001 0.770 ± 0.006 23.60 ± 0.28 
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vehicle (DMSO). After 6 hours of cells being exposed to the inhibitor, samples were 
collected and protein was extracted in order to confirm the appropriate inhibition of p38 
MAP kinase pathway. Immunoblotting was employed to examine the inhibition; for this 
purpose, a phosphorylated site-specific primary antibody directed against T180/Y182 
p38 was used. The respective total protein (p38) was also analyzed using immunoblots. 
Band intensities were computed, and the activated fraction of MAP kinase protein under 
study was calculated by dividing the band intensity of the phosphorylated protein by the 
respective band intensity of the total protein. As illustrated in Figure 19, a significant 
decrease was observed in the activated fraction of p38 for PEG-Scl2-2 p38 gel compared 
to PEG-Scl2-2 DMSO gel, which suggests that p38 pathway was inhibited. 
 
 
Figure 19. Relative levels of activated p38 ( pp38/p38) for the different hydrogel formulations. Data of 
Scl2-2 DMSO was used for normalization.  
*
indicates a significant difference, p < 0.05. 
 
 
Although the reagent used for inhibiting the activation of p38 MAP kinase is 
considered to be selective, the activation of FAK and ERK1/2 pathways was also 
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examined at day 0 (after 6 hours) of encapsulation to assess potential secondary effects 
of p38 inhibition on other MAP kinases (Figure 20). Phosphorylated site-specific 
primary antibodies directed against TYR 397 FAK and T202/Y204 ERK were used, and 
the respective total proteins (FAK and ERK) were also analyzed. Comparing the levels 
of activation of FAK protein between PEG-Scl2-2 p38 and PEG-Scl2-2 DMSO 
hydrogels, phosphorylation of FAK was significantly lower in PEG-Scl2-2 p38 relative 
to PEG-Scl2-2 DMSO. On the contrary, the active fraction for ERK1/2 was similar in 
both hydrogels (i.e. a significant difference was not observed). Cumulatively, the present 
data associated with initial activation of MAP kinase signaling suggested that 1) 
appropriate inhibition of p38 MAP kinase was observed after 6 hours of encapsulation, 
2) FAK and p38 pathways may have a crosstalk relationship since FAK activation was 
also reduced in the hydrogel that was exposed to the p38 inhibitor and 3) cell responses 
may be associated with inhibition of p38α and FAK MAP kinases.  
 
5.4.3. Cell differentiation 
 
The effect of p38α pathway on the osteogenic differentiation of hMSCs was 
evaluated. Human MSCs in PEG-Scl2-2 hydrogels were cultured in osteogenic medium 
containing dexamethasone, ascorbic acid and β-glycerophosphate and p38 inhibitor for 2 
weeks. Following this time, osteogenic differentiation markers were examined by 
western blot assays. As shown in Figure 21, day 14 levels of various osteogenic markers 
indicated  significant  differences  among  hydrogel  formulations.  Specifically,  cells  in  
 98 
 
 
Figure 20. Activated fraction of FAK and ERK1/2 MAP kinase proteins that was investigated. Data of 
Scl2-2 DMSO was used for normalization.  
*
indicates a significant difference, p < 0.05. 
 
 
PEG-Scl2-2 DMSO gels expressed significantly higher levels of osteopontin than PEG-
Scl2-2 p38 hydrogels (p = 0.04). Also, Runx2 and osterix expression had an apparent, 
although not statistically significant, decrease in PEG-Scl2-2 p38 gels compared to PEG-
Scl2-2 DMSO gels. These data suggests that the p38 pathway may be involved in 
osteogenesis of hMSCs. However, its influence was not completely isolated since FAK 
activation was also affected with the inhibition of p38 MAP kinase.  
That said, the current results suggest that p38 inhibition decreases osteopontin 
levels, in contrast to initial results which indicated initial p38 activation decreases 
osteopontin levels. This may be due to complex temporal integration of signals over 14 
days of culture. However, it may also be due to the fact that inhibition of one of the 
MAP kinase proteins does not imply that the remaining proteins involved in MAP kinase 
pathways will not be enhanced or inhibited, as well. As noted above, FAK activation 
 99 
 
decreased by the inhibition of p38 pathway but ERK activation was not affected. JNK 
MAP kinase is another critical shunt in the MAP kinase pathway that may potentially be 
affected by p38 inhibition. There are several reports that have shown that JNK MAP 
kinase plays an important role in osteogenesis [145, 149, 150]. In particular, Guicheux et 
al. reported that both p38 and JNK pathways are involved in osteogenesis. Indeed, they 
showed that inhibition of p38 was associated with decreased alkaline phosphatase (ALP) 
activity, and that inhibition of JNK was associated with a reduction in osteocalcin (OC) 
production [149]. In addition, Jaiswal et al. showed that JNK activation plays a role in 
the late stage of osteogenic differentiation since its activation was related with 
extracellular matrix synthesis and increased calcium deposition, the two hallmarks of 
bone formation [145]. As a result, future work will require to include investigation of the 
JNK pathway in hMSC osteogenesis in order to better understand the potential causative 
relationship with Scl2 proteins, specifically, and the signaling induced by their integrin 
α1 and α2 binding sequences. 
The present results and the data obtained in the study of the effect of collagen-
mimetic proteins in human mesenchymal stem cell osteogenesis could explain the 
temporal relationships of kinase activation. The cumulative data suggests that FAK and 
p38 MAP kinases could be activated at different times, and likely regulate distinct 
biological functions in osteogenesis, such as commitment, differentiation and 
maturation. In order to gain a more detailed understanding of the reciprocal influence of 
MAP kinase proteins in osteogenesis, study of their activation thorough time is 
necessary as well as how the different osteogenic markers that were investigated vary 
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with time. Consequently, future studies that involve the analysis of MAP kinase 
activation and osteogenic marker progression at an increased number of time points will 
be necessary in order to help to better understand the crosstalk that may exist between 
the different MAP kinase pathways in osteogenesis. This will help to gain insight in the 
influence of the initial activation that is mediated by integrin α1 and α2 binding 
sequences. 
 
 
Figure 21. Expression of osteogenic markers osterix, osteopontin and Runx2 by western blot. For 
western blot assays, six samples per formulation (day 14) were analyzed. For the purpose of comparison, 
western blot measures for each protein have been normalized to the corresponding measure for Scl2-2 
DMSO gel.  
*
indicates a significant difference, p < 0.05. 
 
 
5.5. CONCLUSION 
 
In the current study, the influence of p38 MAP kinase was investigated toward 
the goal of deconvoluting the impact of integrin α1 and α2 in hMSC osteogenesis. Scl2-2 
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protein was conjugated into PEGDA hydrogels and p38 pathway was inhibited to 
evaluate its effect on osteogenic differentiation of encapsulated human MSCs. The 
inhibition of p38 pathway reduced the expression of osteogenic markers (Runx2, OPN 
and osterix), which suggest that this MAP kinase protein may regulate osteogenesis in 
hMSCs. Nevertheless, FAK activation was also reduced by inhibiting p38 pathway. 
These results confirm that MAP kinase pathways play an important role in osteogenesis 
and that the extent to which each is activated during differentiation may reflect the 
integration of multiple signals and the balance among FAK, ERK1/2 and p38 MAP 
kinases; as a result, further research is needed for investigation of detailed mechanism of 
osteogenesis regulation. Finally, to gain insight into the origins of the found conflicting 
osteogenic responses, future studies that involve the analysis of MAP kinase activation 
and osteogenic marker progression at an increased number of time points will be 
necessary in order to help to better understand the crosstalk that may exist between the 
different MAP kinase pathways in osteogenesis. 
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CHAPTER VI 
CONCLUSIONS 
 
In this work, the first aim was to compare the osteoinductivity of select ECM 
components in defined 3-D environments toward the improved design of osteogenic 
scaffolds. The ECM components were examined within the context of scaffolds with 
osteogenic moduli. The associated temporal evolution in MSC lineage progression and 
integrin profiles were then characterized, and results indicated that both FG and LN 
enhanced the osteogenic response of encapsulated 10T½ cells. To gain insight into the 
origins of the osteogenic response associated with FG and LN, the integrin-based 
interactions supported by these ECM components were investigated. The results 
indicated that integrin α2 and α6 appeared to play an important role in MSC osteogenic 
differentiation. 
Nonetheless, although results revealed that FG and LN supported osteogenesis 
and that integrin α2 and α6 play a role, native biomolecules such as FG and LN also 
support an array of additional signals which guide cell behavior. Consequently, the 
results cannot be definitively linked to integrin α2 and α6 signaling. In order to address 
this limitation, we proposed to probe MSC osteogenic response to collagen-based 
biochemical motifs using novel hybrid hydrogels. Collagen-mimetic protein, termed 
Scl2-1, provided a “blank-slate” into which desired collagen adhesion sequences were 
programmed by site-directed mutagenesis to include receptor binding motifs that interact 
with α1 and or α2 integrin subunits (Scl2-2 and Scl2-3). In this way, the collagen-
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mimetic proteins Scl2-1, Scl2-2, and Scl2-3 were functionalized with photocrosslinking 
sites to enable incorporation into a three dimensional hydrogel matrix. Bioactive 
hydrogels were then fabricated by combining the functionalized Scl2s with PEGDA and 
photocrosslinking via exposure to UV light. Characterization studies confirmed that the 
functionalization of the Scl2 proteins did not disrupt triple helix conformation, integrin 
binding, or cell adhesion. Also, initial cell studies confirmed specific hMSC adhesion to 
Scl2-2 and Scl2-3 proteins and appropriate activation of different MAP kinase pathways 
(FAK, p38α and ERK1 2) due to selective integrin binding. 
Furthermore, the current work also examined the influence of integrin α1 and α2 
binding on hMSC osteogenesis toward the goal of deconvoluting the impact of integrin-
based interactions on associated cell behavior. Scl2-1, Scl2-2 and Scl2-3 proteins were 
conjugated into PEGDA hydrogels and their effects on encapsulated human MSCs were 
evaluated. Following 2 weeks of culture, various osteogenic markers were examined in 
order to assess the impact of integrin α1 and α2 on the observed responses. Contradictory 
results were found in that both PEG-Scl2-2 and PEG-Scl2-3 were osteoinductive, but in 
different ways. Finally, to gain insight into the origins of the observed osteogenic 
responses, the influence of the p38α pathway in hMSC osteogenesis was investigated in 
order to establish its potential causative relationship with Scl2 proteins. The results of 
the p38 inhibition studies showed that the inhibition of the p38 pathway reduced the 
expression of osteogenic markers (Runx2, OPN and osterix), which suggest that this 
MAP kinase protein may regulate osteogenesis in hMSCs. Nevertheless, FAK activation 
was also reduced by inhibiting the p38 pathway. These results confirm that MAP kinase 
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pathways play an important role in osteogenesis and that the extent to which each is 
activated during differentiation may reflect the integration of multiple signals and the 
balance among FAK, ERK1/2 and p38 MAP kinases.  
Further research is needed for investigation of detailed mechanism of 
osteogenesis regulation. Specifically, to gain insight into the origins of the observed 
conflicting osteogenic responses, future studies that involve the analysis of MAP kinase 
activation and osteogenic marker progression at an increased number of time points will 
be necessary in order to help to better understand the crosstalk that may exist between 
the different MAP kinase pathways in osteogenesis. This should significantly advance 
our understanding of the processes associated with MSC osteogenic progression and 
ultimately allow the design of improved osteogenic scaffolds.  
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